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ABSTRACT OF DISSERTATION

LATEXIN’S ROLE IN REGULATING HEMATOPOIETIC STEM AND
PROGENITOR CELLS
Previous studies in our lab identified a novel gene, latexin (Lxn), that
regulates murine hematopoietic stem cells through balancing apoptosis, selfrenewal and proliferation. In these dissertation studies, I performed a series of
experiments to examine the function of Lxn using a Lxn conventional knockout
mouse, and characterize Lxn’s role in the presence of hematopoietic stresses
such as ionizing radiation, cytokines induced-mobilization, and hematopoietic
malignancy.
The first series of experiments was designed to determine the role of Lxn
in hematopoiesis under homeostatic conditions. I found that Lxn-/- mice exhibited
hyperproliferative hematopoiesis, a repopulation advantage and elevated selfrenewal capacity which was intrinsic to the Lxn-/- hematopoietic cells.
Furthermore, I identified a reduction in apoptotic frequency in Lxn-/hematopoietic progenitors, which may account for the expansion seen in the
progenitor population.
In a second series of experiments, I discovered a role of Lxn in the radiosensitivity of hematopoietic cells. I found that loss of Lxn in mice confers
resistance to ionizing radiation. Lxn-/- mice showed rapid hematological
recoveries after radiation exposure at the stem and progenitor cell (HSPC) level.
The ablation of Lxn hindered irradiation-induced apoptosis which may underlie
the radiation resistance through regulating hematopoietic recovery.
In a third series of experiments, I studied the interaction of Lxn-/- stem and
progenitor cells with their microenvironment. Using a granulocyte colonystimulating factor-induced mobilization model, I determined that the ability of
HSPCs to mobilize into the bloodstream was significantly increased in Lxn-/mice. The adhesive properties of hematopoietic cells were compromised in Lxn-/animals. Gene expression studies on progenitor cells identified cell-to-ECM
interactions were down-regulated upon Lxn deletion, implying the enhanced

mobilization efficiency of hematopoietic cells from Lxn-/- mice correlated with
reduced adhesion of hematopoietic progenitor cells to stroma.
Last, but not least, I performed a series of experiments to study the
putative tumor suppressor role of Lxn in hematological malignancy. I found that
Lxn expression was down-regulated in primary tumor and tumor cell lines by
promoter methylation. Overexpression of Lxn inhibited lymphoma cell growth
both in vitro and in vivo. Overexpressed Lxn increased apoptosis frequency by
suppressing the expression of several anti-apoptotic genes, and therefore
reduced the tumor growth.
KEYWORDS: Latexin, hyperproliferative hematopoiesis, radio-resistance, cell
retention, apoptosis

__ Yi Liu
__
Student’s Signature
_September 06, 2013_
Date

LATEXIN’S ROLE IN REGULATING HEMATOPOIETIC STEM AND
PROGENITOR CELLS

By
Yi Liu

Gary Van Zant, Ph.D.
Director of Dissertation

___

_
Steve Estus
Ph.D.
Co-Director of Dissertation

__

_
Bret Smith, Ph.D.
Director of Graduate Studies
_
September 06, 2013
Date

_

_____

I would like to dedicate this dissertation to my husband Xiangrong Li, to my
parents, Ping He and Bin Liu, and to my dearest friends from University of
Kentucky, in appreciation for their unconditional supports and priceless
friendships.

ACKNOWLEGEMENT
For this dissertation, I would like to gratefully and sincerely thank Dr. Gary
Van Zant for his guidance, patience, and most importantly, his friendship during
my graduate studies at University of Kentucky. Life blessed me with the
opportunity to meet Dr. Gary Van Zant. He embraced me as an inexperienced lab
volunteer and kindly gave me the chance to become a graduate student in his lab.
His dedication to scientific research has inspired me to become a qualified
scientist. His mentorship is paramount in equipping me with a faith of life-long
pursuit of knowledge.
Many thanks to my committee members Dr. Steve Estus, Dr. Charlotte
Peterson, and Dr. James Geddes for their encouragement, suggestions, and
guidance both in scientific research and my graduate studies. I also would like to
thank Dr. Misung Jo for serving as the outside examiner for this dissertation. I am
deeply grateful for their insightful comments that helped me complete this
dissertation.
The studies described in this dissertation are built upon studies started by Dr.
Ying Liang, Dr. Erin Oakley and many other individuals in the Van Zant lab. I
would like to express my gratitude to Dr. Ying Liang for her creative work,
thoughtful instruction, and priceless friendship. I also would like to thank Dr. Erin
Oakley and Dr. Scott Bryson for their suggestions and help in editing this
dissertation. Moreover, my appreciation is also given to my colleagues and
friends from my Lab: Kyle Rector, Carol Swiderski, Barry Grimes, Amanda
Waterstrat and Ailing Li. I am very fortunate to have worked in an amicable lab
iii

where I made lifelong friends.
Last but not least, I want to show my appreciation for my parents,
grandparents, and my husband for their faith in me and support for my work. I am
deeply grateful for Xiangrong, my considerate husband, unconditional supporter,
and best friend. I thank him for going through hard times and wonderful
experiences with me.

iv

TABLE OF CONTENTS
ACKNOWLEGEMENT .......................................................................................... iii
TABLE OF CONTENTS ........................................................................................ v
LIST OF TABLES.................................................................................................. x
LIST OF FIGURES ...............................................................................................xi
CHAPTER 1: INTRODUCTION ............................................................................ 1
1.1 Hematopoiesis and hematopoietic stem cell ............................................... 1
1.2 Stem cell niche ............................................................................................ 2
1.2.1 Endosteal niche and vascular niche ..................................................... 3
1.2.2 Cell types in the bone marrow niche ..................................................... 3
1.3 Stem Cell Trafficking ................................................................................... 4
1.3.1 Mobilization ........................................................................................... 5
1.3.2 Homing ................................................................................................. 5
1.3.3 Molecules involved in HSC migration and homing ................................ 6
1.4 Ionizing radiation toxicity ............................................................................. 7
1.4.1 Radiation-induced HSC apoptosis, senescence and tumorigenesis ..... 8
1.5 Identification and quantitation of hematopoietic progenitor and stem cells . 9
1.5.1 Flow cytometric phenotyping ................................................................ 9
1.5.2 Colony-forming unit (CFU) assay........................................................ 11
1.5.3 Cobblestone-area forming cell (CAFC) assay..................................... 11
1.5.4 In vivo transplantation ......................................................................... 13
1.6 Latexin and stem cell ................................................................................ 14
1.7 Experimental goals and significance ......................................................... 16
CHAPTER 2: Loss of Latexin Confers a Hyperproliferative Hematopoiesis and
Altered Self-renewal Capacity in Murine Hematopoiesis .................................... 25
v

2.1 Abstract ..................................................................................................... 25
2.2 Introduction ............................................................................................... 26
2.3 Methods .................................................................................................... 27
2.3.1 Animals ............................................................................................... 27
2.3.2 Generation of Lxn deficient mouse ..................................................... 28
2.3.3 Peripheral blood cell count ................................................................. 28
2.3.4 Hematopoietic cell identification and isolation .................................... 28
2.3.5 Cell Analysis and Sorting .................................................................... 29
2.3.6 Cell cycle and proliferation analysis .................................................... 29
2.3.7 Apoptosis analysis .............................................................................. 30
2.3.8 Colony forming cell (CFC) assay ........................................................ 30
2.3.9 Cobblestone Area Forming Cell (CAFC) Assay .................................. 31
2.3.10 BM transplantation ............................................................................ 31
2.3.11 Western blot ...................................................................................... 32
2.3.12 RNA isolation and quantification ....................................................... 33
2.3.13 Microarray analysis ........................................................................... 33
2.3.14 Statistics ........................................................................................... 34
2.4 Results ...................................................................................................... 34
2.4.1 Generation of Lxn deficient mouse model .......................................... 34
2.4.2 Loss of Lxn leads to hyperproliferative hematopoiesis in Lxn-/- mice . 35
2.4.3 Loss of Lxn induces hyperproliferative hematopoiesis phenotype
through dysregulating progenitor and stem cells ......................................... 36
2.4.4 Loss of Lxn confers a significant competitive advantage and selfrenewal capacity to HSCs. ........................................................................... 37
2.4.5 Decreased apoptosis frequency in Lxn-/- HSPCs may account for
enlarged progenitor and stem cell compartments. ....................................... 39
2.4.6 Functional categories enriched in the differentially expressed genes in
Lxn-/- MPP cells........................................................................................... 40
2.5 Discussion ................................................................................................. 41
2.6 Acknowledgements ................................................................................... 46

vi

CHAPTER 3: Loss of Latexin in Murine Hematopoietic Stem and Progenitor Cells
Mitigates Ionizing Radiation Toxicity ................................................................... 64
3.1 Abstract ..................................................................................................... 64
3.2 Introduction ............................................................................................... 65
3.3 Methods .................................................................................................... 66
3.3.1 Animals ............................................................................................... 66
3.3.2 Ionizing radiation................................................................................. 67
3.3.3 Peripheral blood cell counts. ............................................................... 67
3.3.4 Hematopoietic cell identification and isolation .................................... 67
3.3.5 Cell analysis and sorting ..................................................................... 68
3.3.6 Apoptosis analysis .............................................................................. 68
3.3.7 Colony forming cell (CFC) assay ........................................................ 68
3.3.9 Statistics ............................................................................................. 69
3.4 Results ...................................................................................................... 69
3.4.1 Loss of Lxn mitigates lethal and sub-lethal irradiation with various
doses ........................................................................................................... 69
3.4.2 Loss of Lxn promotes the recovery of hematopoietic stem/ progenitor
cells post radiation exposure ....................................................................... 70
3.4.3 Loss of Lxn facilitates hematologic and immunologic recovery post
radiation exposure ....................................................................................... 71
3.4.5 Lxn ablation diminished radiation-induced apoptosis in hematopoietic
stem/ progenitor cells................................................................................... 73
3.5 Discussion ................................................................................................. 74
3.6 Acknowledgements ................................................................................... 79
CHAPTER 4: Loss of Latexin Compromises Progenitor and Stem Cell Retention
and Results in An Enhanced Mobilization in Murine Hematopoiesis .................. 85
4.1 Abstract ..................................................................................................... 85
4.2 Introduction ............................................................................................... 86
4.3 Methods .................................................................................................... 88
vii

4.3.1 Animals ............................................................................................... 88
4.3.2 Hematopoietic cell identification and isolation .................................... 88
4.3.3 Cell analysis and sorting ..................................................................... 89
4.3.4 Mobilization assay .............................................................................. 89
4.3.5 Colony forming cell (CFC) assay ........................................................ 89
4.3.6 HPC adhesion assay .......................................................................... 90
4.3.6 Microarray analysis ............................................................................. 90
4.3.7 Statistics ............................................................................................. 91
4.4 Results ...................................................................................................... 91
4.4.1 Mobilization of HSPCs is increased in Lxn-/- mice.............................. 91
4.4.2 Loss of Lxn impaired HSPCs adhesion to stromal cells ...................... 93
4.4.3 Decreased levels of adhesive molecules in Lxn-/- mice ..................... 94
4.5 Discussion ................................................................................................. 95
4.6 Acknowledgements ................................................................................... 98
CHAPTER 5: Latexin is Down-regulated in Hematopoietic Malignancies and
Restoration of Expression Inhibits Lymphoma Growth ..................................... 108
5.1 Abstract ................................................................................................... 108
5.2 Introduction ............................................................................................. 108
5.3 Material and Methods .............................................................................. 112
5.3.1 Animal ............................................................................................... 112
5.3.2 Leukemia cell lines ........................................................................... 112
5.3.3 Isolation of CD34+ cells .................................................................... 113
5.3.4 Quantitative real-time PCR ............................................................... 114
5.3.5 Western blots .................................................................................... 115
5.3.6 Genomic bisulfite sequencing ........................................................... 116
5.3.7 5-aza-2’-deoxycytidine treatment ...................................................... 117
5.3.8 Infection of WEHI231 and A20 cells with Lxn expression vector....... 118
5.3.9 Measurement of growth of retrovirally-transduced tumor cells ......... 118
5.3.10 Cell cycle and apoptotic analysis .................................................... 119
viii

5.3.11 Immunohistochemstry of A20 cells treated with potato
carboxypeptidase inhibitor (PCPI) ............................................................. 119
5.3.12 Culture of A20 cells with potato carboxypeptidase inhibitor ............ 120
5.3.13 Statistical analysis .......................................................................... 120
5.4 Results .................................................................................................... 121
5.4.1 Loss of Lxn expression in malignant cells ......................................... 121
5.4.2 Aberrant promoter hypermethylation of Lxn in hematopoietic
malignancy ................................................................................................ 121
5.4.3 Reactivation of Lxn expression with demethylation reagent treatment
................................................................................................................... 122
5.4.4 Suppression of growth of mouse lymphoma cell lines in vitro and in
vivo following ectopic Lxn expression ........................................................ 123
5.4.5 Lxn inhibits tumor cell growth through increasing apoptosis but not via
its canonical function ................................................................................. 125
5.4.6 Down-regulation of Lxn in primary leukemia and lymphoma cells .... 127
5.5 Discussion ............................................................................................... 128
5.6 Acknowledgements ................................................................................. 132
CHAPTER 6: General Discussion and Conclusions ......................................... 144
APPENDIX ....................................................................................................... 151
REFERENCE ................................................................................................... 152
VITA .................................................................................................................. 173

ix

LIST OF TABLES
Table 1.1 Molecules involved in HSC migration and homing. ............................. 20
Table 2.1 Genes differentially expressed in Lxn-/- MPP cells ............................. 57
Table 4.1 GSEA enrichment table of pathways altered in Lxn-/- MPP cells ...... 103
Table 4.2 Gene expression profile of genes in Cell-to-ECM interaction pathways.
......................................................................................................................... 104
Table 4.3 Gene expression profile of genes in Cell-to-Cell interaction pathway.
......................................................................................................................... 106
Table 5.1 Carboxypeptidase A3 (Cpa3) is highly expressed in stem/progenitor
cells. ................................................................................................................. 143

x

LIST OF FIGURES
Figure 1.1 Developmental hierarchy of the hematopoietic system. .................... 18
Figure 1.2 The endosteal and vascular niches. .................................................. 19
Figure 1.3 Mouse peripheral blood leukocyte dynamics after 6.5 Gy irradiation. 21
Figure 1.4 Radiation-induced apoptosis, senescence and tumorigenesis. ......... 22
Figure 1.5 Cobblestone-forming cell (CAFC) assay. .......................................... 23
Figure 1.6 In vivo transplantation........................................................................ 24
Figure 2.1 Generation of Lxn deficient ( Lxn-/-) mice.......................................... 47
Figure 2.2 Proliferative hematopoiesis in Lxn-/- mouse. ..................................... 48
Figure 2.3 Stem cell and progenitor quantification by using phenotypic marker
and flow cytometry. ............................................................................................. 49
Figure 2.4 Functional analysis of Lxn-/- mice. .................................................... 52
Figure 2.5 Serial transplantation and reciprocal transplantation with Lxn-/- mice
and B6 mice........................................................................................................ 54
Figure 2.6 Alteration in apoptosis in Lxn-/- hematopoiesis. ................................ 56
Figure. 2.7 Thbs-1 expression level in Lxn-/- HSPCs. ........................................ 58
Figure. 2.8 Flow cytometric analysis of lineage distribution in PB. ..................... 59
Figure 2.9 Transplantation strategy. ................................................................... 60
Figure 2.10 Lacking of alteration in cell cycle status and proliferation in Lxn-/HSPCs. ............................................................................................................... 62
Figure 3.1 Kaplan-Meier curves demonstrate survival rate. ............................... 80
Figure 3.2 Ablation of Lxn confers protection of HSPCs against gammairradiation and speeds recovery. ......................................................................... 81
xi

Figure 3.3 Ablation of Lxn promote hematological recovery at HSPC level. ....... 82
Figure 3.4 Lxn ablation in mice diminished radiation-induced apoptosis in
progenitor and stem cells. .................................................................................. 83
Figure 4.1 Flow cytometric analysis of mobilized HSPCs in PB of B6 and Lxn-/mice. ................................................................................................................... 99
Figure 4.2 Mobilization of HSPC in B6 and Lxn-/- mice measured by CFU assay.
......................................................................................................................... 100
Figure 4.3 Adhesion capacities in HSPCs in B6 and Lxn-/- mice...................... 101
Figure 5.1. Decrease or loss of Lxn expression in leukemic and lymphoma cell
lines. ................................................................................................................. 133
Figure 5.2. Hypermethylation of Lxn promoter CpG sites in leukemic cell lines.
......................................................................................................................... 134
Figure 5.3. Overexpression Lxn suppresses growth of A20 lymphoma cell lines.
......................................................................................................................... 136
Figure 5.4. Ectopic Lxn expression increases apoptosis of A20 cells. .............. 139
Figure 5.5. Decreased Lxn expression in stem/progenitor-enriched CD34+ cells
in patients with leukemia and lymphoma. ......................................................... 140
Figure 5.6 Cpa3 is not expressed in A20 cells. ................................................. 142
Figure 6.1 Mechanisms of Lxn in influencing hematopoietic biology through
regulating apoptosis. ........................................................................................ 150

xii

CHAPTER 1: INTRODUCTION
1.1 Hematopoiesis and hematopoietic stem cell
Hematopoiesis is the developmental process of blood formation. Blood is
composed of as many as eight specialized blood cell types, including
granulocytes, lymphocytes, erythrocytes (red blood cells) and thrombocytes
(platelets). Different cell types perform distinct biological functions, ranging from
nutrient and oxygen supply, blood coagulation, and pathogen defense. Since
these blood cells have a limited lifespan, a large pool must be replenished
continuously. In a healthy adult, approximately 1011-1012 new blood cells are
produced daily, by a small number of hematopoietic stem cells (~105)(HSCs)1-3.
HSCs reside in bone marrow (BM) and have the unique capacity to give
rise to a large population of mature blood cells of various lineages. Much like
stem cells from other tissues, pluripotent differentiation potential and highly
conserved self-renewal capacity are common features of HSCs. 1) HSCs reside
on top of the hematopoietic hierarchy. A small number of HSCs are able to
rapidly accomplish their regenerative task via the generation of very proliferative
multi-potent progenitor cells (MPPs). These cells differentiate into lineagecommitted progenitor cells such as common lymphoid progenitor (CLP) and
common myeloid progenitors (CMP). The lineage committed progenitor cells
further differentiate in a series of steps to mature blood cells which have no
differentiation potential (Fig. 1.1). In general, along the hematopoietic hierarchy,
stem and progenitor cells gradually lose differentiation potential from pluripotent
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to unipotent, and this multi-lineage differentiation potential is one of the hallmarks
of stem cells. 2) Another unique feature of HSCs is their capacity to self-renewal.
The self-renewal is defined as: a stem cell produces one daughter cell which
remains as stem cell, and another daughter cell which has more restricted
differentiation and proliferative potential. In this way, HSCs maintain the size of
the stem cell pool, preventing depletion of HSCs by differentiation. 3) Proliferative
capacity is not a unique feature of HSCs. However, the proliferative nature of
HSCs may affect other unique features such as in vivo HSC self-renewal and
differentiation potential 4. The extensive proliferation history leads to loss of stem
cell functional quality which known as replicative senescence5. In sum, all three
features mentioned above are indispensable for HSCs. The intrinsic balance
between proliferation, differentiation and self-renewal is essential for maintaining
hematopoietic homeostasis, robustly restoring injured hematopoiesis (blood loss
or ionizing radiation induced injury), as well as rapidly responding to pathogen
infection.
1.2 Stem cell niche
The hematopoietic stem cell niche is an anatomic location in bone marrow
where HSCs remain quiescent, self-regenerate, proliferate or differentiate in
response to various extrinsic cues. The first study that described the possible
physiological functions of niche cells was conducted in Dr. John Trentin's lab forty
years ago6, 7. They demonstrated an active role of stromal cells in regulating the
differentiation of HSCs. In 1978 Schofield expanded the observations of Trentin
and others and proposed a hypothesis in which HSCs reside in specific
2

microenvironments where HSC fate decisions are made8. The microenvironment
has been termed "niche"6, 7. In recent years, there have been many studies of
the HSC niche to identify the cell types that compose the niche and to determine
the signals that regulate HSC behavior within the niche.
1.2.1 Endosteal niche and vascular niche

Previous studies revealed two types of hematopoietic stem cell niches: the
vascular niche and the endosteal niche (Fig. 1.2). The vascular niche consists of
endothelial cells lining sinusoidal vessels. This particular microenvironment has
been shown to be critical in supporting the differentiation and proliferation of
short-term HSCs and HSC regeneration after injury9. The endosteal niche is
located on the inner surface of the bone cavity and is comprised of a
heterogeneous cell population that includes, endothelial cells, adipocytes, and
osteoblasts10-14 (Fig. 1.2). This niche, in general, is primarily associated with a
capacity to provide signals for HSC quiescence.

The two niches work

cooperatively in a dynamic process that permits HSCs to migrate from a hypoxic
endosteal microenvironment, in a relatively inactive state, to sinusoidal vessels, a
permissive environment that promotes HSC proliferation and differentiation15.
1.2.2 Cell types in the bone marrow niche

Amongst the various cell types within the endosteal niche, osteoblasts
play an important role in reciprocal communication with primitive stem cells16, 17.
In vivo, HSCs are localized spatially close to osteoblasts16, 18 (Fig. 1.2). Ablation
of osteoblasts resulted in a significant reduction in the hematopoietic cell
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population, which indicates a supportive role of osteoblasts in maintaining
HSCs12. Moreover, other niche components such as neuronal cells and
adipocytes have also been shown to be involved in regulating the HSC pool.
Nonmyelinating Schwann cells of autonomic nerves have been shown to be a
critical determinant in maintaining HSC hibernation by activating latent TGFbeta13. Niche adipocytes were discovered as negative regulators of HSCs in a
study using a lipoatrophic mouse model and pharmacological inhibition of
adipocyte formation14. While so many characteristics of the BM niche have been
defined, the crosstalk among niche cells and stem cells, as well as the
mechanisms through which the microenvironment regulates HSC fate, requires
further exploration.
1.3 Stem Cell Trafficking
HSC trafficking is believed to be essential for definitive hematopoiesis
during pre-natal and early post-natal periods. During development, HSCs migrate
from the aorta-gonad-mesonephros (AGM) region, to the fetal liver, and finally to
the BM19. However, HSCs continue to migrate throughout postnatal life. Some
are continuously in blood circulation under homeostasis, but may migrate back to
and reside in BM niches, where they hibernate, proliferate or self-renew. This
two-way commute is central to hematopoietic homeostasis. It is possible that
stem cell move out of the bone marrow may ferry molecules to and from the
niche to other tissues and organs throughout the body.

4

1.3.1 Mobilization

The egression of HSCs from the BM into blood circulation is called
mobilization. During mobilization, HSCs actively move close to sinusoidal vessels,
pass the vascular endothelial wall, migrate into the bloodstream, and then
infiltrate into other tissues (e.g. spleen)20. The release of HSCs from the BM into
the bloodstream is believed to be a physiological phenomenon for maintaining
hematopoietic homeostasis through balancing HSC numbers21.
HPSCs into the bloodstream follows circadian rhythms.

Egress of

Studies showed a

fluctuation of circulating HPSCs peaks 5 hours after the initiation of light and
nadirs 5 hours after darkness22-24. After receiving photic stimulation, the circadian
pacemaker in the central nervous system (CNS) down-regulates the production
of SDF-1 in its niche24. With a compromised SDF-1 dependent HSC retention in
the niche, HSPCs readily enter the circulation24.
Furthermore, HSC migration is manifested and utilized in clinical practice
using cytokine exposure.

Mobilization agents such as cyclophosphamide, 5-

fluorouracil, stem cell factor (SCF), stromal derived factor-1 (SDF-1), and
granulocyte-colony stimulating factor (G-CSF) are used extensively in a clinical
setting to obtain adequate HSPCs from the transplant donors by pushing large
numbers of HSPCs into the peripheral circulation 25-29.
1.3.2 Homing

In contrast to mobilization, HSCs also continuously home back to the BM
niche under homeostasis, or after BM transplantation. The homing of circulating

5

HSCs requires a set of molecular interactions that mediate the sequential
process of endothelial adhesion, rolling and transmigration through the
endothelium. Several molecules are involved in these processes, the most
important ones being adhesion molecules.
1.3.3 Molecules involved in HSC migration and homing

Migration and homing are both mediated by adhesion molecules and their
ligands (Table1.1). Both HSCs and endothelial cells in the niche express
adhesion molecules. In the tethering process, P- and E-selectin on endothelial
cells work co-operatively to bind to P-selectin glycoprotein ligand-1 (PSGL-1, a
glycoform of CD44 in human) on stem cells and progenitors

30-33

. Once stem cell

and progenitors are anchored, stromal derived factor-1 (SDF-1) activates
intergrin by interacting with C-X-C chemokine receptor type-4 (CXCR4), and
induces HSC transmigration through the vascular endothelial cell wall to the
niche

34-36

.

Very late antigen-4 (VLA-4) and VLA-5, both of which belong to

intergrin family, interact with adhesion molecules, particularly vascular cell
adhesion molecule-1 (VCAM-1), and provide rigorous binding

37-39

. Defective

HSC homing or retention most likely indicates down-regulated expression of
adhesion molecules, and results in reduced cell-to-cell or cell-to-extracellular
matrix interaction.
Additional molecules like small GTPase and hormonal signals have been
reported to be involved in HSPC homing and mobilization. Mice defective in RRas (Rac1/Rac2 activator) expression, exhibit decreased BM homing and
increased responsiveness to G-CSF induced mobilization
6

40

. Cdc42, another

small GTPase that mediates adhesion, is activated in aged HSCs

41

. Elevated

levels of cdc42 activity are associated with a decline in HSC retention and
increased mobilization with advanced age41. Furthermore, Parathyroid hormone
(PTH) can effectively induce the mobilization of HSPCs, whereas Prostaglandin
E2 (PGE2) elevates HSC homing efficiency 42-44.
1.4 Ionizing radiation toxicity
Maintaining a stable supply of mature blood cells is essential for nutrient
supply, pathogen defense and tumor surveillance in hematopoiesis. However,
this homeostasis can be perturbed by DNA-damaging agent such as ionizing
radiation. Ionizing radiation is a high-frequency radiation that has very high
energy and the capacity to remove an electron from an atom. When ionizing
radiation passes through a cell, its high energy causes intracellular atoms and
molecules to become excited, or “ionized”. This ionization can break chemical
bonds, produce free radicals, and damage molecules (e.g. DNA, RNA and
proteins), which are vital in biological processes45.
The blood forming-organs, reproductive organs, digestive organs, skin,
bone and teeth are primary targets of radiation. Among the tissues mentioned
above, the blood system is most sensitive to radiation due to its high turnover
rate. In the mouse, after exposure to irradiation, blood cell numbers increase in
the first several days (overshoot stage), then drop off, and reach a nadir at 3-4
weeks (nadir stage)46,

47

(Fig. 1.3). Subsequently, the number of blood cells

begins to increase and reaches a plateau at 8 weeks post irradiation (recovery
stage)46. The recovery stage is the most important period in increasing the
7

survival rate after radiation injury.
1.4.1 Radiation-induced HSC apoptosis, senescence and tumorigenesis

After exposure to ionizing radiation, radiation-induced DNA damage
immediately halts cell cycle progression (cell cycle arrest) (Fig. 1.4). During the
period of cell cycle arrest, DNA repair machinery is triggered and begins to repair
the damage. If the repair is unsuccessful, the cells are removed by a
programmed cell death mechanism (apoptosis). From the studies of the
response of HSCs to ionizing radiation, beginning during the World War II, it has
been learned that a majority of HSCs die after radiation exposure by triggering
apoptosis45, 48. A dose of 4 Gy radiation induced apoptosis in 65% of HSCs (LinSca-1+c-Kit+ cells), and in 50% of primitive progenitors (Lin-Sca-1-c-Kit+ cells)49, 50.
In some cells, the cell cycle arrest becomes permanent. These cells lose
their proliferation capacity and become senescent49. A study on human HSCs
(CD133+ cells) demonstrated that, even though these cells were successfully
repaired, their ability to self-renew was permanently damaged49. An increase in
p16Ink4a expression on HSCs also implies the induction of premature senescence
in these cells49.
In some circumstances, apoptosis and senescence do not functionally
remove all of the damaged cells. A small number of cells survive radiation stress
with chromosome aberrations (Fig.1.4). These cells are dangerous due to their
genomic instability, and have potential to result in tumorigenesis in the future. It
has been previously reported that DNA repair machinery reaches its maximal
effectiveness after a dose of 0.4~0.5 Gy radiation51, 52. Therefore, high doses of
8

radiation or continuous low doses of radiation can readily induce tumorigenesis.
In general, a balance between cell proliferation, senescence and
apoptosis is critical for tissue homeostasis. In this dissertation, I will focus on
Latexin deficiency induced radio-resistance and its role in regulating apoptosis in
irradiated HSCs.
1.5 Identification and quantitation of hematopoietic progenitor and stem
cells
Various assays have been established to measure the number and
functionality of HSCs and their progeny. These assays include in vitro
phenotyping assays, in vitro clonogenic assays, and in vivo transplantation
assays, all of which are used to help enhance our understanding of
hematopoietic progenitor and stem cell biology.
1.5.1 Flow cytometric phenotyping

Advances in flow cytometry over the past decades have revealed
important information on the phenotypes of different hematopoietic cell subsets.
Combining fluorescently labeled antibodies against cell surface receptors with
flow cytometric analysis allows for the identification and isolation of progenitor
and stem cells53, 54. Although multiple approaches have been developed over the
years, a common consensus is that HSCs lack lineage markers (antigens that
expressed on mature granulocytes, macrophages, B and T lymphocytes and red
blood cells), and express stem cell receptors (such as Sca-1 and c-Kit)54-60. The
immunophenotypically identified population (Lineage-/ Sca-1+/c-Kit+ cells, also
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known as LSK cells) is widely accepted as a partially purified HSC fraction in
which approximately 1 in 20 cells exhibits long-term reconstitution ability56, 61-63.
In the past decade, several novel HSC marking strategies have been
developed. CD34 or Flt-3 expression was shown to be associated with a loss of
primitiveness in the LSK population63-65. Antibodies against CD34 and Flt-3
further subdivide the LSK population into three populations (LSK/CD34+/Flt-3+
cells, LSK/CD34+/Flt-3- cells and LSK/CD34-/Flt-3- cells), each of which possess
different engraftment and differentiation potentials63-65. One of the most recent
additions to HSC marking strategies is the application of antibodies against the
SLAM family of receptors66. SLAM family receptors are a group of transmembrane proteins that regulate T lymphocyte development and function66.
Primitive HSCs are highly enriched in the CD150+/CD48- cell population with 50%
HSC activity

66, 67

, which to date is the highest purity of HSC described by

phenotypic identification.
Another HSC isolation strategy relies on the ability of HSC to efflux
chemical compounds. Hoechst 33342 is a fluorescent vital dye that binds to DNA
content in cells68. BM cells stained with Hoechst 33342 and subsequently
observed at two emission wavelengths (Hoechst Blue and Hoechst Red)
revealed a small but distinct population of cells that selectively excluded the
Hoechst 33342 dye. This population was termed the "side population" (SP), and
is highly enriched in HSCs68. This methodology allows for the selection of HSCs
based on cellular activity (multi-drug resistance pumps) rather than the
expression of cell surface phenotypes.
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Flow cytometric phenotyping of HSCs is considered an effective way of
identifying stem cells from heterogeneous BM cells. However, the currently used
stem cell markers are under debate due to the lack of information regarding true
HSCs functional phenotype. Generally, under unperturbed conditions, there is a
good correlation between the phenotype and in vivo reconstitution potential of
HSCs; under stress conditions (aging, chemo/radio therapy or transplantation),
phenotypic isolation strategies vary in their efficiency in selecting HSCs.
1.5.2 Colony-forming unit (CFU) assay

The CFU assay is an informative in vitro assay widely used to detect and
quantify hematopoietic progenitor cells. In this assay, BM, spleen or peripheral
blood cells are mixed with methylcellulose-based medium supplied with a
combination of cytokines, and cultured for one or two weeks69-75. Progenitor cells
of different lineages form colonies which have distinct morphologies. In this assay,
each colony is counted and characterized by lineage according to their
morphologies. Thus, it offers insight into the lineage specificity of cells, rather
than assessing the functional activity of primitive, pluripotent HSCs.
1.5.3 Cobblestone-area forming cell (CAFC) assay

The CAFC assay is an in vitro limiting-dilution assay used to determine the
frequency of hematopoietic cell subsets in a developmental hierarchy (Fig.1.5)7679

. A stromal cell layer (e.g. FBMD-1 cells) is pre-seeded and cultured in 96-well

plates, and allows for in vitro long-term culturing of stem and progenitor cell. After
the stromal cells reach confluency, bone marrow cells are plated on top of them.
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Primitive hematopoietic cells migrate beneath the stromal monolayer and form
cobblestone-areas, a small colony of 10-50 cells. The frequencies of stem and
progenitor cells are determined weekly by scoring each well for the presence of
cobblestone-areas over a period of 5 weeks or longer. It has been shown that the
latency of appearance of a cobblestone area is positively correlated with the
primitiveness of a hematopoietic cells

76, 80

. Thus, cells that form cobblestone-

areas at day 7 to day 21 are considered hematopoietic progenitor cells, and cells
that form cobblestones at day 28

to day 35 or later are considered more

primitive stem. It should be noted that cobblestone areas only present for a week
or less so they aren't counted more than once in successive weeks. A modified
CAFC assay (adhesion assay) can also be used to detect the interaction
between hematopoietic cells and stromal cells81. In this assay, hematopoietic
cells are plated onto a stromal layer and the hematopoietic cells and stromal cells
are allowed to interact for 2 ~ 4 hours. The non-adherent cells are then washed
away, leaving the adherent cells in culture. These adherent cells will form
cobblestone-areas at later time points. The adhesion assay generally measures
the adhesive properties of hematopoietic cells and studies the interaction
between hematopoietic cells and stromal cells.
The CAFC assay is a reliable approach for measuring the frequency of
hematopoietic progenitor and stem cells. However, the in vitro culture conditions
exclude the influence from the systemic cues and does not realistically mimic the
in vivo microenvironment. Furthermore, the CAFC assay lacks measurement of
in vivo homing activities; thus the gold standard for stem cell activity remains in
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vivo repopulation experiments.
1.5.4 In vivo transplantation

The definition of HSC relies on the fact that the cell is able to reconstitute
the entire hematopoietic compartment in a lethally irradiated animal for a long
period. This definition makes the in vivo transplantation assay the ultimate
methodology for identifying the activities of HSCs. The first rigorously quantitative
assay allowing measurement of multi-lineage reconstitution potential in vivo was
reported by Harrison in 198082, 83. It was a competitive repopulation (CR) assay in
which support cells with known HSC activity (competitor cells) and a test cell
population with unknown HSC activity were co-transplanted into lethally
irradiated recipients (Fig. 1.6A). The test and competitor cells were from two
distinct sources, each possessing different cell surface marker isotypes (e.g.
CD45.1 or CD45.2), so as to enable tracing of cell origins. In CR assays, the
HSC activity of test cells is assessed by comparing the proportion of test cellderived cells to competitor cell-derived cells in a recipient's peripheral blood.
Theoretically, with equal numbers of cells, test cells and competitive cells
reconstitute hematopoiesis equally. Thus, any deviation from the 50%
engraftment efficiency indicates either a competitive advantage or disadvantage.
CR assays provide information about HSC reconstitution potential as well as the
competitive capacity. Furthermore, since the competition occurs in a common, in
vivo environment, extrinsic factors such as cytokines and stroma can be ruled out.
CR is a powerful assay to measure the multi-lineage reconstitution
potential of test cells, but in the long run test cells also require self-renewal to
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maintain hematopoiesis over a lifespan, a function that can't be directly
measured by CR. A serial transplantation assay, however, allows the
measurement of the self-renewal capacity by introducing multiple reconstitution
stresses84,

85

. Serial transplantation, as the name implied, is a repetitive

transplantation in which test cells are transplanted from one host to another for
several times over what cumulatively amounts to a mouse lifespan or more (Fig.
1.6B). For the primary transplant, one million test cells (CD45.2 isotype) are
mixed with an equal number of competitor cells (CD45.1 isotype) and are
transplanted to lethally irradiated primary recipients. For the secondary transplant,
ten million recipient cells (from primary recipients) are transplanted into
secondary recipients. The same regimen is repeated for the tertiary and
quaternary transplants. In this way, the self-renewal capacity of the cells will be
reflected by the variation in engraftment efficiency in the peripheral blood in each
successive transplanted recipient.
1.6 Latexin and stem cell
Latexin

contains

222

amino

acids,

and

is

the

only

known

carboxypeptidase A4 (CPA4) inhibitor in mammalian cells. CPA4 belongs to the
zinc-dependent metalocarboxypeptidase (MCP) subfamily A/B. Members of this
family are located in digestive tract, brain, heart, and lung. They participate in
peptide hormone activities to regulate cell proliferation and differentiation. The
overall structure of latexin protein consist of two subdomains, each of which
bears an alpha-helix and a four-strand beta-sheet running anti-parallel86. The two
subdomains are linked by a third alpha-helix. The hydrophobic contacts
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established by the two subdomains embrace the enzyme and perform the
inhibition.

Latexin

shares

no

structural

or

sequence

similarity

with

carboxypeptidase inhibitors in other species. However, latexin has a paralogue
called Tig1 that has up to 30% sequence similarity with latexin. The two genes
are located adjacently on chromosome 3. TIG1 has been thought as an ancestor
gene of Lxn, and is a putative tumor suppressor gene. Its expression is
epigeneticly modified in numerous cancers, including prostate, breast and some
hematopoietic malignancy87. The Lxn expression is also suppressed in some
hematopoietic malignancy such as chronic and acute myeloid leukemia, thus
suggesting a possible role for it in tumorgenesis.
Latexin was first discovered in rat brain as a region specific marker of the
lateral neocortex88, 89. In peripheral nervous system, latexin has been reported to
be involved in pain transmission by studying constitutive Lxn knockout mice.
Animals that have no latexin in the nervous system showed a retard sensitivity to
pain90. Lxn is also highly expressed in rat peritoneal mast cells, as well as mouse
macrophages87,

91

, and its expression is further regulated by several pro-

inflammatory stimuli.
Though latexin has not been reported in neural stem cell compartments,
our lab recently discovered that latexin is a homeostatic regulator of HSC
population size in mice92, 93. We used a forward genetic approach, comparing two
mouse strains, and indentified Lxn as the quantitative trait gene that regulates
HSC pool size in mice. The HSC number in mice bone marrow is inversely
related to quantitative Lxn expression level and is regulated through a concert of
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proliferation, self-renewal and apoptosis. High Lxn expression induces an
increased apoptosis as well as decreased proliferation and self-renew. Latexin
acts as a break not only on HSCs, but also in multi-lineage progenitors and
mature cells in circulation.
1.7 Experimental goals and significance
The experimental goal of this dissertation was to study the function of the
Lxn gene in regulating hematopoietic stem and progenitor cell biology using a
Lxn deficient mouse as model. Four specific aims were proposed and tested to
accomplish this goal:1) to study the phenotypes of Lxn deficient mice in
peripheral blood, spleen and bone marrow and identify the mechanisms
underlying these phenotypes; 2) to explore Lxn function under genotoxic stress
using ionizing radiation; 3) to demonstrate the effect of Lxn on HSC migration
activities and identify the potential target gene(s) of Lxn that regulate HSPC
mobilization; 4) to overexpress Lxn in B cell lymphoma cells and study the
potential tumor suppressor role of Lxn in hematological malignancies.
The Lxn gene has recently been identified as a novel, homeostatic
regulator of hematopoietic stem and progenitor cells through concerted
mechanisms of self-renewal and apoptosis, which increase and decrease along
with Lxn expression levels, respectively. Generally, Lxn acts as an autonomous
brake on the expansion of the hematopoietic stem and progenitor cell
populations. Unrestrained cell expansion brings the risk of genomic instability;
however, finely controlled expansion aids in hematopoietic recovery after
genotoxic insults such ionizing radiation. To my knowledge, the roles of Lxn in the
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development of cancer and in response to ionizing radiation have not yet been
elucidated. Therefore, examining a lymphoma cell line overexpressing Lxn and a
Lxn deficient mouse models may help to establish novel strategies for treating
hematologic malignancies, as well as promoting HSPC recovery in patients
undergoing radiotherapy or following accidental radiation exposure.
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Figure 1.1 Developmental hierarchy of the hematopoietic system.
Long-term HSCs, which are pluri-potent, generate short-term HSCs and multipotent progenitor (MPP) cells, which are multi-potent. MPP cells differentiate into
committed progenitor cells (CLP and CMP), which give rise to 8 types of mature
blood cells in the peripheral blood. This hierarchy pyramid is positively correlated
with cell population size, but negatively correlated with self-renewal and
differentiation capacities.
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Figure 1.2 The endosteal and vascular niches.
HSCs reside in both endosteal and vascular niches. A variety of cells, including
endothelial cells, adipocytes, neuronal cells, and osteoblasts, comprise of stem
cell niche. HSCs localized near osteoblasts in the endosteal niche tend to be
quiescent, whereas HSCs that mobilize to the vascular niche are active in
proliferation and differentiation. Schwann cells wrapping the sympathetic nerve
promote HSC dormancy. Adipocytes negatively regulate HSC pool size.
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Table 1.1 Molecules involved in HSC migration and homing.
Molecules

Function

Reference

CXCR4/SDF-1

HSC homing and mobilization

34-36, 94

CXCR2/GROβ

HSC mobilization

95

PSGL-1/P-selectin or E-

HSC homing and adhesion

33, 96

VLA-4 (CD49d/α4

HSC adhesion, homing,

38, 81

integrin)/VCAM-1

mobilization and HSC quiescent

VLA-5 (CD49e/α4 integrin)/

HSC adhesion and homing

97

Induce HSC proliferation,

43, 44, 98

selectin

VLA-5 receptor
PTH/PPR

homing and mobilization
PGE2/ PGE2R

Proliferation, homing and HSC

42

survival
CD44/Osteopontin

HSC adhesion and homing

17, 32, 99

Rho GTPase (Cdc42)

HSC homing and HSC retention

40-42

CD26

HSC homing and mobilization

100, 101

(negative regulation)

Adhesive molecules and their ligands, small GTPases, and hormones that are
involved in HSC migration and homing.
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Figure 1.3 Mouse peripheral blood leukocyte dynamics after 6.5 Gy
irradiation.
After exposed to 6.5 Gy gamma irradiation, blood leukocytes increase in the first
several days (overshot stage), then drop off, and nadir at 3-4 weeks (nadir stage).
Subsequently, the number of blood cells begins to increase and reaches a
plateau at 8 weeks post irradiation (recovery stage).
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Figure 1.4 Radiation-induced apoptosis, senescence and tumorigenesis.
After exposure to ionizing radiation, radiation-induced DNA damage stops cell
cycle progression. The DNA repair machinery is then triggered to repair the
damage. Successfully repaired cells proliferate to repopulate hematopoiesis.
However, when the repair is unsuccessful, the cells are removed by apoptosis or
senescence. A small number of cells can survives radiation stress with
chromosome aberrations, and may cause tumorigenesis in the future.
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Figure 1.5 Cobblestone-forming cell (CAFC) assay.
The stromal layer (e.g. FBMD-1 cells) is pre-seeded and cultured in 96-well
plates. After the stromal cells reach confluency, test cells are plated on top of the
stromal monolayer in a limiting dilutions. Primitive hematopoietic cells (HSCs or
progenitors) migrate beneath the stromal monolayer and form cobblestone-areas.
The frequencies of stem and progenitor cells are determined by scoring each
well weekly for the presence of cobblestone-areas.
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A

B

Figure 1.6 In vivo transplantation.
(A) In competitive repopulation (CR) assays, 1x106 WBM test cells (CD45.2) are
mixed with an equal number of competitor cells (CD45.1), and retro-obitally
injected into lethally irradiated (9 Gy) CD45.1 recipient mice. (B) In serial
transplantation assays, 1x106 WBM test cells (CD45.2) are mixed with an equal
number of competitor cells (CD45.1), and retro-obitally injected into CD45.1
primary recipients. For secondary transplants, 10x106 unfractionated bone
marrow cells were harvested from primary recipients (CR recipients) 15 or 16
weeks post transplantation and transplanted into lethally irradiated secondary
recipients. The same regimen is repeated for tertiary and quaternary transplants.
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CHAPTER 2: Loss of Latexin Confers a Hyperproliferative Hematopoiesis
and Altered Self-renewal Capacity in Murine Hematopoiesis

2.1 Abstract
Previous studies in our lab have identified that a novel gene, latexin (Lxn),
acts endogenously in murine hematopoietic stem cells (HSCs) to negatively
regulate population size by enhancing apoptosis and decreasing self-renewal
and proliferation. To further investigate the functionality of Lxn in hematopoiesis,
we generated a constitutive knock-out mouse model (Lxn-/- mouse). We
determined that this mouse model exhibited hyperproliferative hematopoiesis
including bone marrow hypercellularity, splenomegaly with myeloid cell infiltration,
and peripheral blood leukocytosis. The bone marrow compartment of these
animals also displays expansion of early progenitor populations. In accord with
our original findings, both a repopulation advantage and elevated self-renewal
capacity were observed in competitive repopulation and serial transplantation
assays in this mouse model. Reciprocal transplantation using lethally irradiated
Lxn-/- or B6 mice as recipients showed that the repopulation advantage is
intrinsic to the hematopoietic cells, and not to the microenvironment. Furthermore,
we found that there is a reduction in apoptotic frequency in hematopoietic
progenitors, which may account for an enlarged progenitor compartment in the
bone marrow. These data indicate that loss of Lxn results in hyperproliferative
hematopoiesis, a competitive growth advantage, and enhanced self-renewal
capacity, all of which are hematopoietic cell-intrinsic. Microarray studies
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performed on a purified stem cell population (HSCs) identified Thrombospondin-1
(Thbs-1) as a potential target of Lxn, and its expression level is down-regulated
in Lxn-/- stem cells. In future studies, we plan to study downstream signaling
pathways of Lxn, focusing on Thbs-1.
2.2 Introduction
Latexin was first discovered in rat brain as a region specific marker of the
lateral neocortex88, 89, 102, 103. In the peripheral nervous system, latexin has been
reported to be involved in pain transmission90. Animals that have no latexin in the
nervous system showed a delayed sensitivity to pain. Lxn is also highly
expressed in rat peritoneal mast cells, and mouse macrophages, and is
differentially expressed along the hematopoietic hierarchy with the highest levels
in the most primitive stem cells91-93. Our lab used a forward genetic approach,
comparing two mouse strains, to indentify Lxn as the quantitative trait gene that
regulates variation in HSC pool size in the mice92, 93. The HSC number in mice
bone marrow is inversely correlated to quantitative Lxn expression level and is
regulated through concerted effects on proliferation, self-renewal and apoptosis92,
93

. High Lxn expression induces increased apoptosis as well as decreased

proliferation and self-renewal, and vice versa.
The Latexin protein contains 222 amino acids, and is the only known zincfinger metallocarboxypeptidase inhibitor in mammalian cells86, 104, 105. However, it
shares no structural or sequence similarity with carboxypeptidase inhibitors in
other species. Lxn has a paralogue called tazarotene-induced gene1 (Tig-1),
which is a putative tumor suppressor gene87, 106. To test the hypothesis that Lxn
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is a putative tumor suppressor gene like Tig-1, we studied Lxn function in
hematopoietic malignancy. We found that Lxn expression is highly downregulated in a extensive list of leukemia and lymphoma cancers through the
mechanism of promoter hypermethylation107 (As seen in Chapter 5). Restoring
the expression of Lxn inhibits tumor growth in vitro and in vivo by enhancing
apoptosis in tumor cells.
For these studies, we generated a Lxn constitutive knock-out mouse to
study the its function in hematopoieisis. We found that Lxn-/- mice exhibited
hyperproliferative hematopoiesis, a cell-autonomous repopulation advantage and
elevated self-renewal. A reduced apoptotic frequency in progenitors was found in
Lxn-/- BM cells, which may account for the enlarged progenitor population. Thbs1, which expression was down-regulated in Lxn-/- stem and progenitor cells, was
identified as a potential target of Lxn.
2.3 Methods
2.3.1 Animals

C57BL/6 mice (B6) (8-16 weeks) and B6.SJL/BoyJ (CD45.1) recipient
mice (8-16 weeks) were purchased from The Jackson Laboratory (Bar Harbor,
ME). Latexin constitutive knockout mice were generated by Taconic/Artemis
(Germantown, NY) and used at a young age (8-16 weeks). All animals were
housed in the animal facilities of the University of Kentucky under pathogen-free
conditions according to NIH-mandated guidelines for animal welfare. They were
fed with food and water ad libitum.
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2.3.2 Generation of Lxn deficient mouse

Latexin constitutive knockout mice were commercially generated under
contract to Taconic/Artemis (Germantown, NY) and used at young age (8-16
weeks). The knock-out strategy is described in Results.
2.3.3 Peripheral blood cell count

Animals were anesthetized with isoflurane from Butler Animal Health
Supply (Dublin, OH). Peripheral blood was collected from retro-orbital venous
plexus into EDTA-coated microtainer from Becton, Dickinson and Company
(Franklin lakes, NJ).

Circulating leukocytes, erythrocytes and platelets were

counted by analyzing 20 ul of blood using a Hemavet 950 from Drew Scientific
(Dallas, TX).
2.3.4 Hematopoietic cell identification and isolation

Bone marrow (BM) cells were flushed from the femora and tibiae into
Hanks balanced salt solution (HBSS) with 2% fetal bovine serum (FBS)(both
from Life Technologies, Carlsbad, CA). Progenitor cells were discriminated from
stem cells by the lack of cell surface antigens characteristic of cells committed to
individual lineages. Antibodies against these antigens included CD5 and CD8a,
B220, Mac-1, Gr-1, and Ter119 were biotinylated. Strepavidin secondary antibody
was used to detect lineage negative cells. To further purify primitive stem cells,
stem cell markers Sca-1 and c-Kit, as well as CD34 and Flt3 were incorporated
into the staining procedure. Phenotypes of purified stem cells are lineage-, c-Kit+,
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Sca-1+, CD34-, and Flt3-. Lineage-committed progenitor cells, including common
myeloid

progenitor

(CMP),

granulocyte/monocyte

progenitor

(GMP),

megakaryocyte/erythroid progenitor (MEP) and Common lymphoid progenitor
(CLP), were identified by the markers FcgR, IL7R, CD34 and Flt3. The isolation
strategy is shown in Fig. 2.2A. Dead cells were excluded by propidium iodide (PI)
selection that stains exposed double-strand DNA. All monoclonal antibodies were
purchased from eBioscience (San Diego, CA), Biolegend (San Diego, CA), or BD
pharmingen (San Jose, CA).
2.3.5 Cell Analysis and Sorting

BM cells were analyzed and sorted on a FacsAria II flow cytometer
(Becton Dickinson, Franklin Lakes, NJ). Cells were sorted into phosphate
buffered saline (PBS) containing 0.5% FBS for further use. Each experimental
group was sorted independently. Flow cytometry and FACS data were analyzed
using FlowJo software (Tree star, Ashland, OR).
2.3.6 Cell cycle and proliferation analysis

Cell cycle analysis was performed using Ki-67 and 7AAD. BM cells were
harvested and stained as described above, and then fixed and permeabIlized
using the Fix and Perm kit from Invitrogen (Camarillo, CA). Nuclear staining of Ki67 was performed using the fluorochrome-conjugated anti-mouse Ki-67 antibody
from BD pharmingen (San Jose, CA).
In vivo 5-bromo-2-deoxyuridine (BrdU) incorporation was used to
enumerate proliferative cells. For immediate incorporation, mice were injected
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introperitoneally with BrdU (1 mg/kg of body weight) and bone marrow was
harvested 1 hr later for measurement of BrdU incorporation into recently
synthesized DNA. For long-term incorporation, BrdU (BD Pharmingen, San Jose,
CA) was administered at a concentration of 0.5 mg/mL in drinking water that was
changed every 3 days. BM cells were harvested at 1hr (short term), 3 days and 5
days (long term) after incorporation, then labeled with a cocktail of HSC cell
markers (CD5, CD8a, B220, Mac-1, Gr-1, Ter119, c-Kit+, Sca-1+, CD34-, and Flt3). Subsequent co-labeling with BrdU and HSC cell markers enabled the
determination of cell proliferative status in different progenitor and stem cell
populations.
2.3.7 Apoptosis analysis

BM cells were prepared and immuno-fluorescently stained as described
above. The fluorochrome-conjugated apoptotic marker, Annexin V, along with
DNA dye, 7-AAD, (both from BD Pharmingen, San Jose, CA) was used to identify
apoptotic and necrotic cells. Stained cells from Lxn-/- animals and B6 animals
were analyzed by flow cytometer.
2.3.8 Colony forming cell (CFC) assay

Methylcellulose-based culture media was pre-made with Complete
MethoCult Media (Stem Cell Technologies, Vancouver, Canada) containing
cytokines including stem cell factor (SCF), IL-3 and IL-6. For this assay, 1 x 104
whole BM cells in 100 µL HBSS were thoroughly admixed with 1 mL complete
MethoCult media, plated into 6-well petri-dish and incubated at 37°C. Individual

30

well of triplicates were scanned on day 7 and 14 to identify relative distribution
and formation of lineage specified colonies.
2.3.9 Cobblestone Area Forming Cell (CAFC) Assay

A monolayer of FBMD-1 stromal feeder cells was seeded in 96-well tissue
culture-treated plates. After 7 to 10 days (when feeder cells grew confluent),
wells were seeded at doses of 333, 1000, 3000, 9000, 27000 or 81000 whole BM
(erythrocyte depleted; see below) cells from Lxn-/- or B6 mice. Individual wells
were screened at days 7, 14, 21, 28, 35, 42, and 49 for the presence of
cobblestone areas. The CAFC media (IMDM, supplemented with 20% of horse
serum and 1 x 10-5 M hydrocortisone) was changed weekly.
2.3.10 BM transplantation

In competitive repopulation (CR) assays, 1x106 WBM cells from Lxn-/mice or B6 test cells (both CD45.2) were mixed with an equal number of
competitor cells (CD45.1) and retro-obitally injected into lethally irradiated (9 Gy)
B6.SJL/BoyJ CD45.1 recipient mice. Recipients were bled from the retro-orbital
sinus at 5, 10 and 15 or 16 weeks post transplantation to test engraftment
efficiency. Erythrocytes were depleted by hypotonic lysis using NH4Cl. The
leukocytes were stained in triplicate with fluorescent-conjugated monoclonal antiCD45.2 and anti-CD45.1 antibodies, as well as B220, Thy1, Mac-1 and Gr-1
lineage markers (BD pharmingen, San Jose, CA). Samples were analyzed using
a FACScan instrument (Becton-Dickinson Immunocytometry Systems,).
For serial transplantation, in primary transplants, one million test cells
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(CD45.2 isotype) are mixed with an equal number of competitor cells (CD45.1
isotype) and then transplanted into lethally irradiated primary recipients. In
secondary transplants, 10x106 unfractionated bone marrow cells were harvested
from primary recipients (15 or 16 weeks post transplantation) and transplanted
cells into lethally irradiated secondary recipients. The same regimen was
repeated for tertiary transplantation. At each transplant, PB and BM cells were
analyzed as described above. The competitive advantage and self-renewal
capacity of HSCs was analyzed by comparing the percentage of Lxn-/--derived or
B6-derived cells at each round of transplantation.
In reciprocal transplantation, 5x106 unfractionated bone marrow cells
(B6.SJL/BoyJ, CD45.1) were transplanted into either B6 or Lxn-/- recipients (both
are CD45.2). At the 5, 10 and 15 weeks post transplantation, PB and BM cells
were analyzed as described above. The microenvironmental effects were
analyzed by assessing how well the recipient genotype facilitated engraftment
efficiency.
2.3.11 Western blot

For detecting Lxn and Gfm-1 proteins, total protein was extracted from BM,
spleen, liver and brain using protein lysis buffer containing a protease inhibitor
cocktail. Samples were subjected to denaturing PAGE (Novex, 10% Bis-Tris gel),
and electrotransferred to Immunobilon-P membranes (Millipore), which were
subsequently blocked and probed with anti-Gfm-1 (Abcam, Cambridge, MA) or
anti-latexin

primary

antibody.

Primary

antibodies

were

detected

with

phosphatase–conjugated secondary antibodies (Santa Cruz Biotechnology) and
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electrochemifluorescent (ECF) reagent (Pharmacia Biotech) according to the
manufacturer's instructions. The membrane was scanned and bands were
detected and analyzed using a Molecular Dynamics STORM 860 system and
Imagequant Software. The polyclonal IgG rabbit antibody against latexin was
generated from the Lxn-specific amino acid sequence CKHNSRLPKEGQAE at
the C terminus and was produced by Bethyl Laboratories (Montgomery, TX).
After the detection of Gfm-1/Lxn antibodies, membranes were stripped in
40% methanol and a buffer containing 100 mM

-mercaptoethanol, 2% SDS and

62.4 mM Tris-HCl. The stripped membranes was reprobed with antibody to

-

actin (Santa Cruz Biotechnology) and detected as described above.
2.3.12 RNA isolation and quantification

RNA for qRT-PCR was purified using RNeasy Mini Kit (Qiagen,
Germantown, MD). Total RNA was reverse transcribed with High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Predesigned
Taqman real-time primer/probes sets for Thbs-1 (Applied Biosystems, Foster City,
CA) were obtained and PCR was performed using TaqMan Universal Master Mix
(Applied Biosystems, Foster City, CA) on a ABI7500 Real-Time PCR system
(Applied Biosystems, Foster City, CA). Expression levels were normalized to
Gapdh and compared with the ΔΔ threshold cycle method.
2.3.13 Microarray analysis

Microarray experiments were performed on fresh BM Multipotent
progenitor cells (LSK/CD34+/Flt-3+) obtained from three wild type and three Lxn-/-
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biological samples (each of which was pooled from more than 10 individual
animals) using Affymetrix Gene Chip MoGene-1_0-st-v1 Arrays (Santa Clara,
CA). Microarray data were normalized based on the RMA method. To identify
differentially expressed genes comparing B6 versus Lxn-/- mice, we used the
limma package in R/Bioconductor and a p-value<0.01 was used as the cutoff to
select a list of candidate genes.
2.3.14 Statistics

Statistical significance between means was determined by a two-way
Student t test.
2.4 Results
2.4.1 Generation of Lxn deficient mouse model

From previous studies, we learned that Lxn acts as negative regulator of
HSC population size through balancing proliferation, apoptosis and self-renewal.
To further explore the in vivo roles of Lxn, we generated Lxn deficient (Lxn-/-)
mice using a gene targeting method (Fig. 2.1A). The mouse Lxn gene contains
six exons. A gene targeting construct to flank a region of exon 2-4 by LoxP sites.
Exons 2-4 were removed after in vivo Cre-mediated deletion in targeted allele.
Lxn-/- mice appear normal, are produced at the normal Mendelian ratio, and
show no obvious abnormalities in development with either males or females.
The Lxn gene is embedded in the intron of another gene, G-elongation
factor, mitochondrial 1(Gfm1), in the opposite orientation. The deletion of Lxn
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exons 2-4 resulted in the deletion of a portion of Gfm-1 intron 13. To test the
absence of latexin protein and the integrity of Gfm-1 protein, we used western
blot and antibodies against Lxn and Gfm-1 protein. The results revealed that
latexin protein is not expressed in the BM, spleen, liver and brain of Lxn−/− mice,
and Gfm-1 expression is intact in Lxn-/- mice, as in B6 wild type mice (Fig. 2.1B).
2.4.2 Loss of Lxn leads to hyperproliferative hematopoiesis in Lxn-/- mice

To investigate the function of Lxn and its effect on hematopoiesis, we
examined the spleen, peripheral blood and bone marrow in Lxn-/- mice. Lxn-/mice showed splenomegaly (Fig. 2.2A) with a significant increase in spleen
weight due to the expansion of red pulp. We also found an increase in Mac-1/Gr1 positive monocytes and granulocytes in the spleen, suggesting monocyte and
granulocyte infiltration into Lxn-/- spleens (Fig. 2.2B). In the peripheral blood of
Lxn-/- mice, we found a significant increase in white blood cells (WBCs) and
platelets (Fig. 2.2C) compared to wild type animals. Amongst WBC subtypes,
absolute numbers of neutrophils and lymphocytes were increased by
approximately 50% in Lxn-/- mice, whereas monocytes were increased almost
100%. (Fig. 2.2C). However, despite the observation of increased absolute
numbers of granulocytes, lymphocytes and platelets, analysis of lineage
contributions in PB indicated a lineage skewing that favored lymphoid-lineage
cells, especially B lymphocytes (Fig. 2.8). Furthermore, the bone marrow of Lxn/- mice was hypercellular with a 20% increase in the numbers of mononucleated
cells (Fig. 2.3B) in femurs. Together, these findings, which include splenomegaly,
leukocytosis and hypercellular bone marrow, demonstrate that Lxn-/- mice
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develop hyperproliferative hematopoiesis in both PB and BM.
2.4.3 Loss of Lxn induces hyperproliferative hematopoiesis phenotype through
dysregulating progenitor and stem cells

Next we examined the progenitor and stem cell compartments in the BM
using both flow cytometry and functional assays. We found that the absolute
numbers of common lymphoid progenitors (CLPs), common myeloid progenitors
(CMPs) and granulocyte-monocyte progenitors (GMPs) were significantly
increased (up to 50 %) in Lxn-/- mice compared to their wild type counterparts
(Fig.

2.3D)(Phenotypic

isolation

strategy

shown

in

Fig.

2.3A).

The

megakaryocyte-erythrocyte progenitors (MEP) were increased in Lxn-/- mice, but
did not reach statistical level of significance (Fig. 2.3D). Further, we observed 50%
expansion of lineage-cKit+Sca-1+ (LSK) cells in Lxn-/- mice. This expansion was
due to an increase (~100%) in the multipotent progenitor (MPP) population. The
absolute numbers of phenotypic short-term HSCs (ST-HSCs) and Long-term
HSCs (LT-HSCs) remained static (Fig. 2.3E). The colony-forming cell unit (CFU)
and cobblestone-area forming cell (CAFC) assays are two classical in vitro
experiments to measure the functional capacity of progenitor and stem cells.
Here we used both to determine the effect of Lxn on hematopoietic cell functional
capacity. An increased number of day 14 colony-forming cells per 104 BM cells
was observed in Lxn-/- mice compare to B6 mice (Fig. 2.4A). These data
demonstrated that there were increased numbers of progenitors in the BM of
Lxn-/-, consistent with our flow cytometric data. CAFC assays revealed
significantly more day 35 cobblestones in Lxn-/- animals (Fig. 2.4B). The cells
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formed day 35 cobblestones in CAFC assays are commonly considered as stem
cells. In our results, the increased day 35 cobblestones indicated up-regulated
HSC numbers in Lxn-/- animals. However, the competitive repopulation unit
(CRU) assay, the gold standard in numerating the HSC number, found no
difference between the HSC numbers in Lxn-/- and B6 mice (data not shown).
Therefore, we considered that there were increased numbers of cells only in the
progenitor population, not but in the most primitive stem cell population.
2.4.4 Loss of Lxn confers a significant competitive advantage and self-renewal
capacity to HSCs.

To further investigate the effect of Lxn knockout, we performed BM
competitive repopulation assay and serial transplantation experiments. For the
competitive repopulation experiments, one million BM cells from either wild type
B6 mice (CD45.2 isotype) or Lxn-/- mice (CD45.2 isotype), along with same
number of competitor B6.SJL cells (CD45.1 isotype), were transplanted into
lethally-irradiated recipients (Fig. 2.9A). Fifteen weeks after transplantation,
granulocytes (Mac-1+/Gr-1+ cells) and B lymphocytes (B220+ cells) were
enriched in the PB of Lxn-/- mice compared to the ratio used for transplantation
(1:1) (Fig. 2.4F). Over time, the proportion of Lxn-/- donor-derived cells gradually
increased in PB, BM and BM LSK cells (Fig. 2.4C, D and E), suggesting a
competitive advantage of Lxn-/- cells.
We then tested the self-renewal capacity of Lxn-/- HSCs in serial
transplant experiments in which they, along with B6.SJL (CD45.1 isotype) BM
cells, competed for engraftment in lethally irradiated B6.SJL recipients. For the
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primary transplant, one million test cells (CD45.2 isotype) were mixed with an
equal number of competitor cells (CD45.1 isotype) and were transplanted into
lethally irradiated primary recipients. For the secondary transplant, ten million
recipient cells (from primary recipients) were transplanted into secondary
recipients. The same regimen was repeated for the tertiary transplants (Fig. 2.9B).
At each transplant, PB, BM and BM LSK cells were analyzed. The percentages
of Lxn-/- and B6 cells in each compartment were compared. Lxn-/- stem cells
showed a sustained competitive advantage in each population (BM and BM LSK
cells) at primary, secondary and tertiary transplants (Fig. 2.5B and C),
demonstrating that they retained self-renewal capacity under replicative stresses.
At the tertiary transplant, the number of Lxn-/- donor-derived BM and LSK cells
remained high (Fig. 2.5C), whereas the number of their progeny

(PB cells)

dropped to the same level as that of the wild type. This observation may be
explained by replicative senescence.
The BM microenvironment influences HSC lineage fate decisions and
HSC function. The proliferative hematopoiesis can arise from hematopoietic cells
themselves. It also can be induced by cues from the microenvironment
endogenously. In previous studies, we observed that hyperproliferative
hematopoiesis in Lxn-/- mice is transplantable, indicating this phenotype is at
least partially cell intrinsic. To investigate the extrinsic effects, we performed
reciprocal transplants (Fig. 2.9C). Congenic wild-type cells (CD45.1 isotype)
were transplanted into lethally irradiated Lxn-/- or B6 recipient mice. By 5, 10 and
15 weeks post transplantation, there was no difference in donor-derived
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leukocytes in PB between the two groups (Fig. 2.5D). Thus, the proliferative
hematopoiesis observed in Lxn-/- mice is cell-autonomous, and was not induced
by the Lxn deficient microenvironment. However, the donor-derived myeloid cells
were

significantly

suppressed

in

Lxn-/-

recipients,

indicating

Lxn-/-

microenvironment has an influence on lineage preference (Fig. 2.5E). Skewing
toward the myeloid lineage conceals the myelo-proliferation in Lxn-/- mice,
explaining the significantly increased myeloid cells in transplants of Lxn-/- BM
cells (Fig. 2.4F), but not in Lxn-/- mice (Fig. 2.8).
Ultimately, CR, serial transplantation and reciprocal transplantation
experiments showed that loss of Lxn confers a competitive advantage and
increased self-renewal capacity to hematopoietic cells at the level of the HSC
(cell intrinsic).
2.4.5 Decreased apoptosis frequency in Lxn-/- HSPCs may account for
enlarged progenitor and stem cell compartments.

As previously reported, Lxn expression positively regulates apoptosis but
negatively influences proliferation and self-renewal (and vice versa)92, 93. In this
study, we found a proliferative hematopoiesis caused by dysregulation at the
level of the MPP. To explore the mechanism underlying the phenotype, we
studied cell cycle, proliferation, and apoptosis in Lxn-/- hematopoietic cells. BrdU
labeling and Ki-67 staining of hematopoietic cells showed no significant
difference in cell cycle and proliferation status between Lxn-/- and B6 animals
(Fig. 2.10A, B and C). We found decreased numbers of PI-/Annexin V+ cells in
MPP, ST-HSC and LT-HSC populations in Lxn-/- mice compared to B6 mice (Fig.
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2.6A and B), suggesting that Lxn positively regulates apoptosis in stem and
progenitor cells. The apoptotic frequency of Lxn-/- cells was reduced the most in
the MPP population (50% increase). Thus, the observed MPP expansion may be
caused by a decreased rate of apoptosis.
2.4.6 Functional categories enriched in the differentially expressed genes in
Lxn-/- MPP cells.

To gain insight into the molecular mechanisms by which loss of Lxn
induced the various hematopoietic phenotypes, we examined the gene
expression profiles. Microarray experiments were performed in LSK/CD34+/Flt-3+
BM cells obtained from B6 and Lxn-/- mice using Affymetrix Gene Chip MoGene1_0-st-v1 arrays. Using a significance threshold of 0.01, we identified 650 genes
that were differentially expressed between Lxn-/- and B6 LSK/CD34+/Flt-3+ cells.
Some of the most highly under-expressed or expressed genes were identified
(Tab. 2.1). Thbs-1 is one of most highly down-regulated genes, Its expression
level was decreased 4-fold in Lxn-/- hematopoietic multi-potent progenitor
populations (data not shown). To study Thbs-1 as the target gene regulated by
Lxn, we tested Thbs-1 expression at the level of transcript (using quantitative
real-time PCR) in hematopoietic cells. Consistent with microarray results, the QPCR analysis revealed that thbs-1 expression gradually decreased along
hematopoietic differentiation hierarchy, in parallel with Lxn expression (Fig. 2.7).
We also examined the Thbs-1 expression level in FDC-P1 cells (a hematopoietic
stem and progenitor cell line) overexpressing Lxn. The results showed that
ectopic Lxn up-regulated Thbs-1 expression in vitro, indicating that Lxn is an up-
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stream regulator of Thbs-1 (data not shown). However, the mechanism
underlying Lxn regulation of Thbs-1 expression has not been elucidated in these
studies. The next logic step for this research will be study Lxn signaling pathway
focusing on Thbs-1.
2.5 Discussion
In these studies, we found that Lxn-/- mice exhibited hyperproliferative
hematopoiesis, including bone marrow hypercellularity, splenomegaly with
myeloid cell infiltration, and peripheral blood leukocytosis, which may caused by
decreased apoptosis. We also showed a cell-autonomous repopulation
advantage and elevated self-renewal capacity in Lxn-/- mice, indicating that loss
of Lxn leads to enhanced stem cell function. Lxn has been identified as a novel
regulator of hematopoietic stem cell population size through balancing apoptosis,
proliferation and self-renewal93. Congenic mice expressing low expression levels
of Lxn exhibited decreased apoptosis activities, but increased self-renewal
capacity and HSC frequency in BM cells. In our studies, loss of Lxn induced
decreased apoptotic activities, increased self-renewal capacity, and increased
day 35 cobblestones in CAFC assay, which is consistent with previous findings.
However, competitive repopulation unit (CRU) experiments do not show any
alteration in functional HSC frequencies in Lxn-/- mice compared to B6 mice
(data not shown), supported by the results that the numbers of phenotypically
identified long-term and short-term HSCs in Lxn-/- mice were not altered
compared to B6 mice. This may be due to the fact that the effective window of
Lxn activities is limited and/or its effect in regulating HSC population size is dose41

dependent. Relative high or low levels of Lxn expression may regulate the HSC
population size, however, the absence of Lxn during hematopoiesis may not
influence the number, but the other functional properties of HSCs. The
inconsistency between the CRU and CAFC results may be explained by the
controversy of the correlation between the days of appearance of a cobblestone
area and the primitiveness of the stem cell. The phenotypic HSCs (Lin-Sca-1+cKit+CD34-Flt-3-CD150+) can form cobblestones continuously from day 28 to day
64 after plating (unpublished data). Therefore, the frequency of day 35
cobblestones does not represent the accurate numbers of HSC, and leaves the
gold standard in enumerating HSCs with the CRU assay.
The hematopoietic stem cell niche is an anatomic location in the BM
where HSCs remain quiescent, self-regenerate, proliferate or differentiate in
response to various extrinsic cues. Direct interactions between stromal cells and
stem cells, or indirect interactions through cytokines secreted by stromal cells are
critical for stem cell fate decisions. Proliferative hematopoiesis is generally
considered to be intrinsic to hematopoietic cells. However, recent studies have
provided support for the role of the microenvironment in coordinating many
aspects of hematopoietic biology. Studies utilizing transgenic mice such as RAR
gamma and Nf1 have demonstrated that microenvironmental cues may influence
stem cell self-renewal capacity, alter lineage distribution, and induce proliferative
hematopoiesis108,

109

. Given that the microenvironment is known to be an

important regulator of stem cell fate, it is reasonable to speculate that the niche
cells could induce the phenotypes observed in Lxn-/- mice model. In this study,
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we demonstrated a proliferative hematopoiesis, which is transplantable and
therefore cell-intrinsic. Under homeostasis, Lxn-/- mice showed increased
leukocytes and platelets in PB as well as increased cellularity and an expanded
HSPC population in the BM. After transplanting Lxn-/- or B6 BM cells with an
equal number of competitor cells, Lxn-/- cells showed better engraftment
efficiency compared to B6 cells (60% recipient engraftment for Lxn-/- cells vs. 40%
engraftment in recipient receiving B6 cells). Further, hematopoiesis in Lxn-/- mice
showed lineage skewing toward the B cell lymphoid lineage. We also observed
this phenotype in recipients transplanted with Lxn-/- BM cells. Although the
transplantation studies show that the proliferative hematopoiesis and lineage
skewing are cell-autonomous, these data cannot rule out the effects of extrinsic
factors. We performed reciprocal transplants to clarify this issue. Results from
reciprocal transplants showed no significant difference of engraftment efficiency
was induced by the loss of Lxn in the microenvironment. However, there was a
modification in lineage distribution. Myeloid lineage cells were significantly
decreased in the Lxn-/- microenvironment, whereas Lxn-/- cell showed a slight
increase in the numbers in the background microenvironment. These
observations indicate that loss of Lxn in the stem cell niche does not influence
the competitive advantage, but may modify the lineage distribution to favor
lymphoid cells.
The positive correlation between Lxn expression and apoptotic activity in
hematopoietic cells has been previously reported93, 107. Mutations in other proapoptotic genes such as p53 are found in hematopoietic malignancies and, in
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many cases, are thought to be the initiating mutations that generate pre-leukemic
cell at HSC level. Apoptosis is an intrinsic mechanism which scavenges preleukemic cells and protects chromosome integrity. The mutations that generate
pre-leukemic cells are thought to escape apoptosis. Overexpression of Lxn in
tumor cells suppressed tumor growth both in vitro and in vivo, demonstrating a
pro-apoptotic role of Lxn (as seen in Chapter 5). Further, we found decreased
apoptotic frequency in Lxn-/- cells, which may underlie the proliferative
hematopoiesis we observed in the BM of Lxn-/- mice. Will this proliferative
hematopoiesis lead to hematological malignancies? To answer this question, we
examined the cells after a series of transplantation. In primary transplants, Lxn-/derived BM and LSK cells were approximately 100% more than B6 derived BM
and LSK cells. These advantages persisted in secondary and tertiary transplants,
indicating an advanced self-renewal capacity in Lxn-/- HSCs. On the other hand,
Lxn-/- derived PB cells in recipients were 50% more than B6 derived PB cells.
However, this trend did not persist upon tertiary transplants. Instead of taking
over the entire hematopoiesis in tertiary transplant recipients, the Lxn-/- derived
PB cells showed no significant difference compared to B6 derived PB cells,
indicating a reduction in differentiation from BM cell to PB cell that may due to
replicative senescence, or a physiological optimum in which Lxn-/- transplanted
cells maintained a maximal occupation in donor’s hematopoiesis through self(apoptosis) or systemic regulation (phagocytosis)110. In another series of
experiments (Chapter 3), we treated Lxn-/- and B6 mice with 6.5 Gy sub-lethal
doses of radiation and monitored their hematopoietic recovery up to 90 days post
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radiation. No significant difference has been identified in PB leukocyte counts
and BM cellularity in irradiated Lxn-/- mice compared to B6 mice. These
observations imply that the loss of Lxn will not induce tumorigenesis in
hematopoietic cells. However, this hypothesis is not definitive because no
pathological examination has been performed on Lxn-/- BM. A hyperproliferative
hematopoiesis can be induced by increased proliferation as well. In previous
studies performed on congenic mice, we found that proliferative activities are
negatively correlated with Lxn expression level93. However, we did not observe
any changes in proliferation and cell cycling in Lxn knockout mice, or in tumor
cells overexpressing Lxn. The consensus congenic interval on chromosome 3
contains approximately 30 Mb and is composed of a large number of genes. It is
possible that the proliferation trait linked to this congenic interval may be
accounted for by genes other than Lxn.
In these studies we have shown that the proliferative hematopoiesis in
Lxn-/- cells is accounted by the increase in MPP populations, in which the cell
population expanded the most. So we performed microarray experiments on
purified MPP populations from Lxn-/- and B6 mice. We identified Thbs-1, as a
putative target for Lxn using microarray analysis; Loss of Lxn significantly downregulated the expression of Thbs-1. Thbs-1 is a glycoprotein that mediates the
cell-to-cell and cell-to-ECM interactions. It plays a very important role in the niche
in binding to various extracellular matrix ligands such as fibrinogen, fibronectin,
collagens, TGF- , some matrix metalloproteinases, and to cell surface receptors
including CD36 and CD47111, 112. Loss of Thbs-1 in mouse model showed a radio

45

resistance and regulated radiation-induced apoptosis through CD47 mediated
signaling pathway112,

113

. It also has been reported that Thbs-1 is involved in

tumorigenesis as a tumor suppressor gene, similar to Lxn107, 114. Its expression is
either down-regulated or absent due to hypermethylation in cancer cells. Thbs-1
deficient mice developed tumor earlier in a p53 null background, supporting its
role as a putative tumor suppressor gene115. Further, Thbs-1 positively regulates
apoptosis116. It regulates radiation-induced apoptosis through CD47 signaling
pathway112, 117.To test the hypothesis that Thbs-1 expression correlate with Lxn
expression, we overexpressed Lxn in FDC-P1 cells. Using Q-PCR we found that
in FDC-P1 cells overexpressing Lxn, the expression level of Thbs-1 was upregulated with Lxn overexpression. The studies mentioned above indicate Thbs-1
may be a potential target of Lxn.
In conclusion, I found that loss of Lxn induced hyperproliferative
hematopoiesis resulting from decreased apoptosis. Loss of Lxn also confered a
cell-autonomous repopulation advantage and elevated self-renewal capacity,
indicating enhanced stem cell functions in Lxn-/- animals.
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Figure 2.1 Generation of Lxn deficient ( Lxn-/-) mice.
(A) The Lxn wild-type locus, the targeting vector, and the Lxn targeted allele with the
Lxn constitutive knock out allele. (top to bottom). Coding regions are shown as filled
squares labeled with exon numbers. The targeting vector introduced a functional
excision sequence flanking exons 2 to 4 of the Lxn gene that resulted in the excision
of exons 2-4 after in vivo Cre deletion. (B) Western blots of Lxn expression in various
tissues of wild type B6 and Lxn-/- mice. Total protein from BM, spleen, liver and brain
were probed with anti-Lxn or anti-Gfm-1 antibody, respectively.
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Figure 2.2 Proliferative hematopoiesis in Lxn-/- mouse.
(A) Enlarged spleens and expanded red pulp in Lxn-/- mice (n=11) compared with
wild type B6 mice (n=12). (B) Flow cytometry analysis using lineage-specific markers,
Gr-1/Mac-1 (myeloid), B220 (B cell) and Thy-1 (T cell), comparing the proportion of
each cell types in the spleens of Lxn-/- and B6 mice (n>10 in each experiment). (C)
Peripheral blood cells were quantified by using the Hemavet cell counter. The
numbers of total white blood cell, lymphocyte, neutrophil, monocyte and platelet
were compared between Lxn-/- and B6 mice (n>20 in each experiment). * indicated
a P<0.05 hereafter. Error bar represented standard deviation (SD) hereafter if not
indicated.
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Figure 2.3 Stem cell and progenitor quantification by using phenotypic
marker and flow cytometry.
(A) Flow cytometric analysis of immunological cell surface makers were used in
identifying the frequency of progenitor and stem cells. Serial gating and marker
panels for each subpopulation (LT-HSC, ST-HSC, MPP, CLP, CMP, GMP, MEP and
LSK) are listed above.
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Figure 2.3 continues (B) BM cellularity (cell number/femur) in Lxn-/- mice (n=26)
compared with wild type B6 mice (n=8). (C) Flow cytometric analysis showed an
increased LSK population in Lxn-/- BM cells that due to an expanded MPP
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population. (D) and (E) Flow cytometric studies revealed that LSK cells, multi-potent
progenitors (MPPs) and lineage committed progenitors (CLPs, CMPs, and GMPs)
were relatively increased in Lxn-/- BM cells. In (C), (D) and (E), each experiment
was repeated 3 times, and at least 3 animals were pooled in each group.
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Figure 2.4 Functional analysis of Lxn-/- mice.
(A) Day 14 colony-forming cells formed per 104 cells in Lxn-/- mice (n=5) and B6
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mice (n=4). (B) The frequency of CAFCs formed at day 35 in Lxn-/- (n=4) and B6
(n=3) animals. Panels C, D, E and F are flow cytometric analysis of competitive
repopulation experiments with Lxn-/- and B6 mice (n=10 in each experimental group).
(C) Flow cytometric analysis of engraftment efficiency of donor derived cells in PB of
recipients at 5, 10 and 15 weeks post competitive transplantation. (D) Flow
cytometric analysis of the percentage of donor-derived cells in BM of recipients at 15
weeks after competitive transplantation. (E) Flow cytometric analysis of the
percentage of donor derived LSK cells in PB of recipients at 15 weeks post
competitive transplantation. (F) Determination of the lineage distribution of myeloid,
T and B cells in the PB of donor animals in transplanted recipients at 15 weeks post
transplantation. Error bar represented standard error of the mean (SEM) in Fig. 2.4B.
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Figure 2.5 Serial transplantation and reciprocal transplantation with Lxn-/mice and B6 mice.
(A, B and C) Self-renewal analysis of HSCs using serial transplantation. Lxn-/- (two
independent experiments; n=10) or B6 (two independent experiments; n=10) derived
peripheral blood leukocytes (A), BM nucleated (B) and BM LSK cells (C) were
analyzed 15 weeks post transplantation in primary, secondary and tertiary recipients.
(D and E) 5x106 unfractionated BM cells were transplanted into either B6 (n=5) or
Lxn-/- recipients (n=5). (D) Donor-derived PB leukocytes were analyzed At the 5, 10
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and 15 weeks post transplantation. (E) Lineage distribution of donor-derived myeloid,
T and B cells in PB cells 15 weeks post transplantation.
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Figure 2.6 Alteration in apoptosis in Lxn-/- hematopoiesis.
(A) Flow cytometric analysis of BM cells stained with Annexin V (plus PI)
distinguished cell subsets that are apoptotic (PI- /Annexin V+) in multiple cell subpopulations.(B) Decreased frequency of apoptotic cells in Lxn-/- mice compared to
B6 mice in MPP, ST-HSC and LT-HSC populations.
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Table 2.1 Genes differentially expressed in Lxn-/- MPP cells
Gene

Contrast

HSPA1A

+3.6

RNASE3

+2.0

TSEN15

+1.9

GAS5

+1.9

HSPS1

+1.8

KIR3DL2

-1.76

GFI1B

-1.77

SLC18A

-1.83

TRPC6

-2.3

THBS-1

-3.49

Microarray experiments were performed in LSK/CD34+/Flt-3+ MPP BM cells obtained
from B6 and Lxn-/- mice using Affymetrix Gene Chip MoGene-1_0-st-v1 arrays.
Table 2.1shows top five of the most highly under-expressed or expressed genes with
a significance threshold of 0.01.
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Figure. 2.7 Thbs-1 expression level in Lxn-/- HSPCs.
Thbs-1 expression levels along hematopoietic differentiation hierarchy were
identified by Q-PCR.
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Figure. 2.8 Flow cytometric analysis of lineage distribution in PB.
Flow cytometry using lineage-specific markers, Gr-1and Mac-1 (myeloid cells), Thy-1
(T cells), and B220 (B cells), showed an altered lineage distribution in PB in Lxn-/mice (n=13) compared to B6 mice (n=8).
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A

B

C

Figure 2.9 Transplantation strategy.
(A) In competitive repopulation (CR) assays, 1x106 WBM cells from Lxn-/- mice or B6
test cells (both CD45.2) were mixed with an equal number of competitor cells
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(CD45.1), and retro-obitally injected into lethally irradiated (9 Gy) CD45.1 recipient
mice (B6.SJL/BoyJ). (B) In serial transplantation, one million test cells (CD45.2
isotype) are mixed with an equal number of competitor cells (CD45.1 isotype) and
are transplanted to lethally irradiated primary recipients. At 15 or 16 weeks post
transplantation, 10x106 unfractionated bone marrow cells were harvested from
primary recipients and transplanted cells into lethally irradiated secondary recipients.
The same regimen was repeated for tertiary transplantation. (C) In reciprocal
transplantation, 5x106 unfractionated bone marrow cells (CD45.1) were transplanted
into either B6 or Lxn-/- recipients (both CD45.2).
measured at 5, 10 and 15 weeks transplantation.
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Engraftment efficiency was

Figure 2.10 Lacking of alteration in cell cycle status and proliferation in
Lxn-/- HSPCs.
(A) a representative scatter plot for Ki67 cell cycle analysis. Flow cytometric analysis
of BM cells stained with Ki-67 (combined with DNA dye 7-AAD) distinguishes cell
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subsets that in G0 (Ki-67- 7-AAD-), G1 (Ki-67+ 7-AAD-), and S/G2/M (Ki-67+ 7-AAD+)
phase. (B) Cell cycle status in Lxn-/- and B6 MPP populations. (C) Proliferative
profile of HSPC subsets. Mice were exposed to BrdU for three days prior to analysis.
MPPs, ST-HSCs and LT-HSCs were analyzed for BrdU incorporation (BrdU+).
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CHAPTER 3: Loss of Latexin in Murine Hematopoietic Stem and Progenitor
Cells Mitigates Ionizing Radiation Toxicity
3.1 Abstract
Bone marrow injury is one of the major adverse side effects of radiation
and chemotherapy; however, treatments that can mitigate such injury are very
limited. To manage radiation or chemotherapy induced bone marrow injury, we
need a better understanding of how radiation harms bone marrow cells and their
environment, as well as how bone marrow cells react to such stress. In this study,
we discovered a role for Latexin (Lxn) in the radio-sensitivity of hematopoietic
stem and progenitor cells. We found that loss of Lxn in mice confers resistance to
lethal and sub-lethal radiation. Lxn deletion protected 3 out 5 mice (60%) from 8
Gy irradiation, while no mouse survived in the wild type group. After exposure to
sub-lethal irradiation, the LSK cell population expanded ~5-fold two weeks post
irradiation in Lxn-/- animals, suggesting a rapid recovery to radio-resistance at
the HSC/HPC level. Further, Lxn-/- mice displayed an enhanced hematologic and
immune recovery 3 - 14 days after irradiation, with elevated numbers of total
leukocytes, lymphocytes, granulocytes and platelets. We then studied the
underlying mechanism that accelerates regeneration of hematopoiesis in bone
marrow after irradiation, and found that ablation of Lxn suppressed apoptosis in
primitive progenitor cells (LSK). In conclusion, our data indicate that Lxn
promotes irradiation-induced apoptosis and loss of Lxn conferred a radiation
resistance through regulating hematopoietic recovery. These findings provide a
novel potential therapeutic target for protecting HSPCs in patients undergoing
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radiotherapy or exposed to environmental radiation.
3.2 Introduction
Maintaining a stable supply of mature blood cells is essential for nutrient
supply, pathogen defense, and tumor surveillance in hematopoiesis. However,
this homeostasis can be perturbed by DNA-damaging agents such as ionizing
radiation. Ionizing radiation is high-frequency radiation that has the capacity to
remove an electron from an atom. When ionizing radiation pass through a cell, its
high energy causes intracellular atoms and molecules to become excited, or
“ionized”. This ionization can break chemical bonds, produce free radicals, and
damage molecules45. At low doses of ionizing radiation, hematopoietic cells
trigger a rapid recovery response and amend certain levels of damage46,

47

.

However, DNA mutation may still occur that could lead to tumorigenesis in the
future. When exposed to high doses of ionizing radiation, hematopoietic cells fail
to repair themselves and undergo programmed cell death (apoptosis)

45, 48

.

Therefore, ionizing radiation induced-apoptosis is necessary to balance
tumorigenesis prevention and organismal survival. We propose that low levels of
apoptotic activity are beneficial to tissue regeneration and may promote the
restoration of hematopoiesis when cells are exposed to high doses of ionizing
radiation.
We previously discovered a role for Lxn in inhibiting tumor growth through
promoting apoptosis in cancer cells107 (Chapter 5). Ectopic overexpression of Lxn
in murine lymphoma cells (A20 cell line) slowed their growth rate in vitro and
inhibited tumor formation in vivo by significantly increasing apoptosis through the
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down-regulation of two anti-apoptotic genes: Bcl-2 and Pim-2107. Furthermore, in
mice lacking Lxn expression (Lxn-/-) we observed expanded hematopoiesis due
to decreased apoptosis activity in progenitor and stem cells (Chapter 2). These
phenomena are consistent with what we previously observed in a study with
congenic animals in which Lxn expression was positively correlated with
apoptotic frequency in hematopoietic cells93. These findings implicate Lxn as a
pro-apoptotic factor, and prompted us to explore Lxn function under genotoxic
stress, such as radiation, where apoptosis is critical to tissue regeneration.
In the present study, we demonstrated that deletion of Lxn allows mice to
withstand lethal and sub-lethal doses of radiation. Remarkably, loss of Lxn
protected hematopoietic progenitor and stem cells from ionizing radiation, and
accelerated both hematopoietic and immunologic recovery. Further, Lxn
deficiency significantly suppressed radiation-induced apoptosis in hematopoietic
progenitor and stem cells. In conclusion, our findings provide evidence that
deletion of Lxn may be a novel strategy for promoting HSPC recovery in patients
undergoing radiotherapy or following accidental radiation.
3.3 Methods
3.3.1 Animals

Young C57BL/6 (B6) mice (8-16 weeks) were purchased from The
Jackson Laboratories (Bar Harbor, ME). Latexin constitutive knockout mice were
generated by Taconic/Artemis (Germantown, NY) and used at a young age (8-16
weeks). Male animals were used in this study. All animals were housed in the
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animal facilities of the University of Kentucky under pathogen-free conditions
according to NIH-mandated guidelines for animal welfare and were given food
and water ad libitum.
3.3.2 Ionizing radiation

The mice and cells were exposed to various doses of radiation (6.5 Gy, 8
Gy, 9 Gy and split doses of 12 Gy) in a 137 Cs gamma irradiatior (J.L. Shepherd
and Associates, Glendale, GA) at a dose rate of 153 rad/min.
3.3.3 Peripheral blood cell counts.

Animals were anesthetized with isoflurane (Butler Animal Health Supply,
Dublin, OH). Peripheral blood was collected from retro-orbital venous plexus into
EDTA-coated microtainer tubes (Becton, Dickinson and Company, Franklin lakes,
NJ).

Circulating leukocytes, erythrocytes and platelets were counted by

analyzing 20 ul of blood using a Hemavet 950 (Drew Scientific, Dallas, TX).
3.3.4 Hematopoietic cell identification and isolation

Bone marrow cells were flushed from the femora and tibiae using a 1 ml
syringe and 22G needle into Hanks balanced salt solution (HBSS) with 2% fetal
bovine serum (FBS) (Gibco, Grand Island, NY). Progenitor cells were
discriminated from stem cells by the lack of cell surface antigens characteristic of
cells committed to individual lineages.

Antibodies against these antigens

included CD5 and CD8a, B220, Mac-1, Gr-1, and Ter119 were biotinylated.
Strepavidin secondary antibody was used to detect lineage negative cells. To
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further purify primitive stem cells, the stem cell markers Sca-1 and c-Kit were
incorporated into the staining procedure. Dead cells were excluded by propidium
iodide (PI) that stains exposed double-strand DNA. All monoclonal antibodies
were purchased from eBioscience (San Diego, CA), Biolegend (San Diego, CA),
or BD Pharmingen (San Jose, CA).
3.3.5 Cell analysis and sorting

Bone marrow cells were analyzed and sorted on a BD FacsAria II flow
cytometer (Becton Dickinson, Franklin Lakes, NJ). Cells were sorted into
phosphate buffered saline (PBS) with 0.5% FBS for further use. Flow cytometry
data was analyzed using FlowJo software (Tree star, Ashland, OR).
3.3.6 Apoptosis analysis

Bone marrow cells were prepared and stained as described above. The
fluorochrome-conjugated apoptotic marker Annexin V along with Propidium
Iodide (PI) (both from BD Pharmingen) were used to identify apoptotic cells (PI/Annexin V+). Stained cells from Lxn-/- animals and B6 animals were analyzed by
flow cytometer.
3.3.7 Colony forming cell (CFC) assay

Methylcellulose-based culture media (MethoCult) was purchased from
Stem Cell Technologies, Vancouver, Canada and contained the following
cytokines: stem cell factor (SCF), IL-3 and IL-6. For this assay, 5 x 104 whole BM
cells in 100 µL HBSS were thoroughly admixed with 1 mL complete MethoCult
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media, plated into petri-dishes, and incubated at 37°C. Individual wells of
duplicates were counted on day 10 to quantify lineage specific colonies.
3.3.9 Statistics

Statistical significance between means was determined by a two-way
Student t test.
3.4 Results
3.4.1 Loss of Lxn mitigates lethal and sub-lethal irradiation with various doses

From previous studies, a pro-apoptotic role of Lxn has been observed93,
107

. In order to further study Lxn function in response to hematopoietic stress

induced-apoptosis, we used Lxn constitutive knock-out mice as a model and
treated the mice with ionizing radiation. The Lxn deficient mouse model was
generated by Taconic/armetis with a deletion of exons 2-4 in the Lxn gene which
results in the disruption of the protein (Chapter 2). We first studied the effects of
loss of Lxn in BM cell radiation resistance. Total body irradiation (TBI) was
administrated to both Lxn-/- mice and B6 control mice. We tested various
dosages of gamma radiation including lethal doses of 8 Gy and 9 Gy, as well as
clinically relevant split doses totaling 12 Gy. We then studied the survival rate for
each treatment. As expected, all of the lethally irradiated B6 animals died within
20 days after receiving a single 8 or 9 Gy dose (Fig. 3.1A). Surprisingly, the
survival rate of Lxn-/- mice was significantly greater. As shown in Fig 3.1A, 60%
of the Lxn-/- mice survived the 8 Gy dose of irradiation and 20% of Lxn-/- mice
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survived the 9 Gy dose. To further characterize the radio-protective effect and
study its implication in medical treatment, we irradiated two experimental groups
with 12 Gy TBI using a fractionated schedule of 2 Gy every 12 hours. Consistent
with our previous results, all of the knockout animals survived, whereas only 4
out of 5 wild type mice survived (Fig. 3.1B).
3.4.2 Loss of Lxn promotes the recovery of hematopoietic stem/ progenitor
cells post radiation exposure

HSCs and HPCs are vital to long-term and short-term recovery after
ionizing radiation. To elucidate the underlying mechanism of radio-resistance in
Lxn-/- mice, we studied the recovery of HSCs and HPCs after radiation exposure.
A single dose of 6.5 Gy TBI (sub-lethal dose) was administrated to both
experimental groups (Lxn-/- mice and wild-type B6 mice). The recovery of HSPC
post irradiation was determined by both flow cytometer (which counts phenotypic
HSPC) and in vitro colony-forming unit (CFU) assay (which measures functional
HSPC) in a time dependent manner. At each time point, we harvested BM cells,
analyzed BM cellularity, and measured the size of the surviving LSK cell
population in both groups. The number of phenotypic HSPCs (LSK cells) in Lxn-/mice was significant greater than B6 mice before irradiation and 3 days after
exposure to irradiation (Fig 3.2A). LSK cell counts dropped dramatically at day 7
in both experiment groups. However, the HSC recovery rate was accelerated in
Lxn-/- mice. The number of LSK cells compartment increased approximately 6fold at day 14 and 3-fold at day 21 in Lxn-/- mice (Fig 3.2A and B). The numbers
of LK (Lin-/c-Kit+/Sca-1-) and LS (Lin-/c-Kit-/Sca-1+) cells were also increased at
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day 14, though not to the same extent of LSK cells. These data indicate that
deletion of Lxn selectively protects primitive cells more so than differentiated cells
(Fig 3.2B).
In flow cytometric analysis, we used phenotypic markers to quantify HSPC
numbers. To further identify the numbers of functional HSPCs, we performed
CFU assays with 5x104 whole BM cells from 6.5 Gy sub-lethally irradiated
animals. The pattern of HSPC recovery in Lxn-/- mice is similar to what we
observed using phenotypic markers. Lxn-/- whole BM cells from mice at day 0, 1,
3,14 and 28 post irradiation formed significantly more colonies, which indicated
an accelerated recovery rate compared to B6 cells (Fig. 3.2C). This observation
supported previous LSK cell population frequency results.
We also observed a similar trend in BM cell recovery. The numbers of
surviving whole BM cells were significantly diminished (24~28 million cells per
femur to less than 3 million cells per femur) shortly after irradiation (day 3), and
subsequently stable returned back to normal levels by day 28 in Lxn-/- mice (Fig.
3.2D). Lxn-/- BM cells showed an accelerated recovery rate over B6 BM cells at
day 7, 14 and 28 (Fig. 3.2D), in accordance with increased tempo in recovery of
HSPCs (Fig. 3.2A). Collectively, our results showed that deletion of Lxn upregulates radio-resistance by promoting HSPC recovery and speeding the
regeneration of BM hematopoiesis after irradiation.
3.4.3 Loss of Lxn facilitates hematologic and immunologic recovery post
radiation exposure

Radiation-induced hematological failure and immune failure are the
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primary causes of low survival after high dose radiation exposure. To further
address the question of how Lxn deletion results in radiation resistance, we
examined the hematologic and immune recovery in a time dependent manner
following radiation exposure. Wild type B6 and Lxn-/- animals were exposed to a
sub-lethal (6.5 Gy) dose of radiation to trigger reversible hematopoietic injury. We
then monitored the rate of recovery of blood cells. As demonstrated in Fig. 3.3A,
loss of Lxn significantly accelerated the recovery of total leukocytes in blood.
Untreated Lxn-/- mice have ~ 30% more leukocytes than their wild type
counterparts (Fig. 3.3A). Leukocytes in both strains dropped to approximately
1,000 cells/ul in peripheral blood one day after irradiation. The number of Lxn-/leukocytes rapidly recovered at day 7 and remained significantly greater than B6
(approximately 100% more) up to day 14. The counts of neutrophils (Fig. 3.3B)
and lymphocytes (Fig. 3.3B and C) had similar recovery patterns as the total
leukocytes. Lxn-/- mice showed a faster recovery over the period from day 7 to
28 compared to B6 animals. The level of neutrophil counts in both groups
overshot normal levels, whereas lymphocytes never fully recovered. Platelet (Fig.
3.3D) counts in both groups recovered to normal by day 28. The number of Lxn-/platelets was significantly greater than B6 platelets 3 ~ 7 after irradiation.
Collectively, a recovery advantage was observed at multiple time points in both
hematologic and immune systems in PB, possibly resulting from accelerated
recovery in HSPCs in BM.
We also studied the lineage distribution of mature blood cells between
granulocyte, monocyte, T-cell and B-cell lymphocytes using various lineage
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markers. The gamma irradiation caused immediate lympho- and myelo-ablation
at day 1 and an altered lineage distribution that favored the myeloid lineage (Fig.
3.3E). The lymphoid lineage started to gradually recover 3 days after radiation.
The distribution of B lymphocytes in Lxn-/- mice recovered to near normal (50%),
but B6 B lymphocytes never fully recovered (30%) (Fig. 3.3E). This result is
consistent with what we observed in animals transplanted with Lxn-/- BM cells.
Lxn-/- cells showed a preference for B-cell production in reconstituted
hematopoiesis. In sum, our results indicate that the recoveries of total leukocyte,
platelet, granulocyte and lymphocyte subsets were accelerated in Lxn-/- mice
following ionizing radiation. Further, Lxn-/- cells favor B cell lineage production in
long-term reconstitution.
3.4.5 Lxn ablation diminished radiation-induced apoptosis in hematopoietic
stem/ progenitor cells

We previously reported that Lxn regulates cell populations through its role
in apoptosis. Here we hypothesized that loss of Lxn renders HSCs and HPCs
more resistant to apoptosis after exposure to ionizing irradiation. To test this
theory, we directly examined the apoptotic frequency using Annexin V staining,
and found the percentage of apoptotic LSK cells was significantly lower in Lxn-/mice after 6.5 Gy sub-lethal irradiation (Fig. 3.4A). During homeostasis, apoptotic
cell frequency is inherently significantly lower in Lxn-/- LSK cells (day 0 in Fig.
3.4A). This low apoptotic frequency was sustained from day 7 to day 28 after
irradiation. On day 14 the percentage of apoptotic LSK cells was 5-fold lower in
Lxn-/- mice compared to B6 mice (Fig. 3.4A, B and C). Notably, the percentage of
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apoptotic cells in Lin-, LK and LS subpopulations diminished along with Lxn
ablation on day 14, but did not reach statistical significance (Fig. 3.4C). The
apoptotic frequency was significantly reduced only in LSK cells, indicating that
loss of Lxn selectively affected the apoptotic rate in primitive BM cells.
3.5 Discussion
Exposure to moderate or high doses of total body irradiation leads to longterm irreversible hematopoietic injury. This injury has been attributed to
quantitative and qualitative damages to hematopoietic cells. Radiation-induced
apoptosis and senescence are the major cellular mechanisms which induce
quantitative or qualitative radiation-induced damage to stem cells, respectively48,
50

. From previous studies we learned that a majority of HSCs die after radiation

exposure by triggering apoptosis49, 118. The apoptotic activity of the cells is critical
for regulating the radiation-resistance and survival rate after exposure to high
doses of radiation.
In vivo proapoptotic functions of Lxn were previously demonstrated in B
lymphoma cells107. Furthermore, in mice lacking Lxn expression (Lxn-/-) we
observed expanded hematopoiesis due to decreased apoptotic activity in
progenitor and short-term HSCs (Chapter 2). These results suggest that Lxn
regulates apoptotic activities of hematopoietic cells. In this chapter, we studied
the function of Lxn in response to ionizing radiation, under which apoptotic
activities are key factors in post radiation recovery, using Lxn deficient mouse as
a model.
We first examined the radio-protective activities of Lxn in murine
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hematopoiesis by studying the survival rates of Lxn-/- and B6 mice after lethal
doses of radiation exposure. When exposed to lethal doses of total body
irradiation (above 7.5 Gy, single dose), death is usually caused by hematological
failure119-121. Three days after radiation, BM cell counts (both leukocytes and
platelets) drop dramatically. Another target organ of irradiation-induced injury
potentially leading to mortality is the small intestine122. However, previous reports
demonstrated a rapid recovery of the small intestine injured at the level when
exposed to 7.5~9 Gy, suggesting that gut injury is not the primary cause of death
at these doses of radiation. In this study, we performed 8, 9, and 12 Gy split
doses of radiation to study Lxn function on the survival rate of Lxn-/- mice.
Administrating 12 Gy TBI using a fractionated schedule of 2 Gy every 12 hours is
a clinically relevant and is roughly equal to a single dose of 7 Gy irradiation123.
We employed this radiation dose in order to demonstrate the potential radioprotective function of Lxn deficiency which may benefit patients undergoing
radiotherapy. The results showed that loss of Lxn leads to the long-term survival
of more than 60% of the Lxn-/- mice irradiated with 8 Gy, whereas all wild type B6
mice succumbed. However, Lxn-/- mice showed only a 20% increases in the
survival rate after 9 Gy as well as split doses of 12 Gy radiation. These results
suggested that the effective window of Lxn deficiency is quite limited and its
effect in mitigating radiation-induced mortalities is dose-dependent.
When given a sub-lethal dose of radiation, leukocyte and platelet counts
drop off shortly after radiation exposure. However, unlike after a lethal dose of
irradiation, HSPCs that survive a sub-lethal dose reconstitute hematopoiesis
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within 8 weeks after radiation exposure50. To further characterize the function of
Lxn in mitigating radiation-induced BM failure, mice were exposed to a 6.5 Gy
sub-lethal dose of total body irradiation. The hematopoietic recovery was closely
monitored and our results show that the loss of Lxn significantly accelerates the
recovery of both leukocytes and platelets. Measurements of CFCs in the BM at
day 10 post radiation conclusively demonstrate the hematopoietic progenitor cell
numbers are increased in Lxn-/- mice. Increased frequencies of BM LSK cells
(stem cells) and LK cells (progenitor cells) indicate that loss of Lxn promotes the
recovery of hematopoiesis at the level of stem cell/progenitor cells. Lxn-/- mice
exhibit an endogenous, proliferative hematopoiesis, including higher levels of
leukocytes, increased BM cellularity, and increased HSC numbers (LSK cells)
under homeostasis (which continuously stay higher during hematologic recovery).
However, this advantage diminishes after hematopoiesis is reconstituted. A
possible explanation for this observation is replicative exhaustion in which stem
cells lose their functional capacity after periods of active proliferation and
differentiation.
How does the loss of Lxn facilitate hematopoietic stem/progenitor recovery
post irradiation? Ionizing radiation produces free radicals that damage DNA
content and induces apoptotic and mitotic death49. As we hypothesized, Lxn
deficiency may protect HSPCs from apoptosis. Our data shown in Fig.3.4
indicates that loss of Lxn decreases apoptosis in irradiated hematopoietic stem
and progenitor cells, especially stem cells (LSK cells). Another possibility that
could induce a rapid recovery after radiation is an advantage in cell proliferation.
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Increased cell proliferation activity will expand the cell population and accelerate
hematologic recovery. In previous studies, we found that the loss of Lxn does not
affect proliferation and cell cycling activities in stem and progenitor cells under
homeostasis. Therefore, in this paper, we did not examine the proliferative
activities during hematologic recovery. However, it is possible that the loss of Lxn
may influence cell cycling status and proliferation after radiation exposure. In the
future we will test the proliferative activities of HSPCs after sub-lethal doses
radiation using BrdU incorporation, which labels newly synthesized DNA in
proliferating cells.
From studies on B lymphoma cells, we found that Lxn overexpression
decreased the expression of the anti-apoptotic gene Bcl-2 and inhibited tumor
cell growth through promoting apoptosis107. Apoptosis is controlled by a balance
of positive (pro-apoptotic) and negative (anti-apoptotic) signals. Decreased levels
of Bcl-2 allow other pro-apoptotic proteins to aggregate and induce apoptosis
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.

Tumor suppressor p53 is a regulator of Bcl-2125, 126. Induction of p53 resulted in a
decreased expression level of Bcl-2125. The p53 signaling pathway is central in
ionizing radiation-induced apoptosis127-129. It is possible that the mechanisms
underlying Lxn -/-induced radio-resistance are involved in p53 and Bcl-2
mediated apoptosis pathways. In future studies, we will test the expression level
of the key players in p53 mediated signaling pathway such as MDM2/X,
phospho-p53, p53, Bcl-2, Bax and Bad using immuno-blots.
Another potential candidate gene involved in Lxn induced-apoptosis is
Thbs-1. We have demonstrated a significantly decreased level of Thbs-1 in Lxn-/-
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multipotent progenitor cell population, compared to wild-type animals. Thbs-1 null
mice showed a radio-resistance130, similar to what we observed in Lxn-/- mice. It
has been reported that Thbs-1 is involved in regulating radiation-induced
apoptosis through CD47-mediated signaling pathway112, 117. In future experiments,
we will study Thbs-1 as a potential target gene of Lxn by overexpressing Thbs-1
in Lxn-/- BM cells and transplant the transduced cells. Radio sensitivities will be
tested in recipients transplanted with transduced or control Lxn-/- cells.
Premature senescence and tumorigenesis are two possible outcomes of
radiation exposure other than apoptosis. It was previously reported that a small
portion of surviving HSCs lose their expansion and self-renewal capacities after
radiation exposure50. In Fig. 3.2 A and B, we showed that HSC numbers (LSK
cells) in Lxn-/- mice were significantly increased compared to B6 mice. But do
these phenotypically defined HSCs function normally? To explore the answer to
this question, CAFC assays or in vivo transplantation assays will be used to
measure the functional activities of HSCs. Also, a small number of cells survive
radiation stress with chromosome aberrations which can result in tumorigenesis.
To address this scenario, we monitored the surviving mice after split doses of 12
Gy radiation for 8 months. Their hematologic and immune parameters remained
within the normal range (data not shown), and no tumorigenesis occurred in
irradiated Lxn-/- mice. These observations suggest that the loss of Lxn confers
little genetic instability while preventing apoptosis after radiation exposure. The
loss of Lxn is unlikely to promote cancer growth in the irradiated mice.
In conclusion, the loss of Lxn protects HSPCs against lethal and sub-lethal
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radiation and promotes hematopoietic and immune recovery post radiation
exposure by regulating apoptotic activities in HSPCs. Studying the mechanisms
underlying Lxn radio-sensitive function provides a novel potential therapeutic
target for protecting HSPCs in patients undergoing radiotherapy and mitigating
toxicity from environmental radiation.
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Figure 3.1 Kaplan-Meier curves demonstrate survival rate.
(A) Kaplan-Meier survival curves of mice exposed to lethal total body irradiation.
B6 and Lxn-/- mice (n=5 for each experimental group) were given a single dose
of 8 or 9 Gy irradiation, and monitored for their survival. (B) Kaplan-Meier survival
curves of mice exposed to clinically relevant total body irradiation. Mice (n=5 for
each experimental group) were given a total of 12 Gy (2 Gy administrated 6
times). * indicated a P<0.05 hereafter.
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Figure 3.2 Ablation of Lxn confers protection of HSPCs against gammairradiation and speeds recovery.
B6 and Lxn-/- mice (n=3 for each experimental group) were irradiated with a sublethal 6.5 Gy dose of irradiation. We then monitored bone marrow progenitor and
stem cell kinetics for 56 days post radiation. (A) The numbers of surviving LSK
cell in one femur were compared between the two groups. (B) Flow cytometric
analysis showed the expanded LSK, LK, and LS cell populations at day 14 post
irradiation for both Lxn-/- and B6 mice. (C) The frequencies of hematopoietic
stem and progenitor cells were determined by in vitro colony forming cell assay.
(D) The numbers of surviving bone marrow cells in one femur were compared
between two groups.
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Figure 3.3 Ablation of Lxn promote hematological recovery at HSPC level.
B6 and Lxn-/- mice (n=3 for each experimental group) were irradiated with a sublethal 6.5 Gy dose and their hematologic and immunologic recovery was
monitored in peripheral blood over 56 days. The counts of total leukocytes (A),
neutrophils (B), lymphocytes (C) and platelets (D) were determined by using a
Hemavet cell counter. (E) Differentiated lineage cells were measured by flow
cytometer using lineage-specific antibodies (Gr-1, Mac-1, B220 and Thy-1).
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Figure 3.4 Lxn ablation in mice diminished radiation-induced apoptosis in
progenitor and stem cells.
B6 and Lxn-/- mice (n=3 for each experimental group) were irradiated with a
sub-lethal 6.5 Gy dose of radiation. Apoptotic activities in HSPCs were measured
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using the apoptotic marker Annexin V and flow cytometry. (A) The flow cytometric
analysis of apoptotic cells on day 14 post irradiation using Annexin-V and DNA
dye staining. (B) Analysis of apoptotic rate dynamics (over 56 days post 6.5 Gy
irradiation) in the LSK population. (C) The apoptotic frequency of LSK, LK, LS
and LIN- sub-populations in Lxn-/- animals in day 14 post radiation.
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CHAPTER 4: Loss of Latexin Compromises Progenitor and Stem Cell
Retention and Results in An Enhanced Mobilization in Murine
Hematopoiesis

4.1 Abstract
Engraftment and maintenance of hematopoietic stem and progenitor cells
(HSPC) depends on their interaction with a specific bone marrow (BM)
microenvironment, commonly known as the niche. Mobilization of HSPCs from
niche into peripheral blood in response to granulocyte colony-stimulating factor
(G-CSF) involves detachment of HSPCs from stromal cells, which make up a
large portion of the niche. The influence of latexin (Lxn) on stem/progenitor cellstroma interactions has not yet been studied. Using G-CSF-induced mobilization
in Lxn deficient (Lxn-/-) mice, we found that the number of phenotypically
identified HSPC (Lin-c-Kit+ cells) mobilized into the bloodstream is about 2-fold
greater in Lxn-/- mice.

In vitro adhesion assays showed that the adhesive

properties of hematopoietic cells are compromised in Lxn-/- animals, perhaps
allowing them to spill into the bloodstream more easily. Microarray experiments
on multipotent progenitor cells identified several pathways that were altered upon
Lxn deletion. The signaling pathways of cell-to-cell and cell-to-ECM interaction
were significantly reduced, implying an enhanced mobilization efficiency in
primitive hematopoietic cells from Lxn-/- mice. These findings may explain the
reduced adhesion of hematopoietic progenitor cells to stroma in Lxn-/- mice.
Amongst the genes that were significantly under-expressed, thrombospondin-1
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(thbs-1) expression level stood out as the most down-regulated in Lxn-/progenitor and stem cells.
4.2 Introduction
Hematopoietic progenitor and stem cells (HSPCs) reside in a cavity with
stromal cells in the bone marrow, and this area is commonly referred to as the
HSC niche. In their niche, HSCs remain quiescent, self-regenerate, proliferate,
differentiate and/or migrate into the peripheral blood in response to various
extrinsic cues. The release of HSPCs from the niche into the bloodstream is
termed " mobilization", during which, HSPCs actively move close to sinusoidal
vessels, pass through the vascular endothelial wall, migrate into bloodstream,
and then infiltrate other tissues (e.g. spleen), or return to the marrow20. HSPC
mobilization is believed to be a physiological phenomenon for maintaining
hematopoietic homeostasis21. Redundant HSPCs in the BM niche egress into the
bloodstream in order to balance HSPC numbers in both systems. This
phenomenon is utilized in clinical practice to obtain adequate HSPCs from a
transplant donor; such that mobilization cytokines are used to push large
amounts of HSPCs into the peripheral circulation for harvesting25-29.
HSPCs are anchored in the niche through direct cell-to-cell and cell-toECM interactions. The adhesive molecules, including members from the intergrin,
cadherin and selectin families, is essential for HSPCs retention34-36. Any
dysregulation in adhesive molecules may affect mobilization of HSPCs.
Previous

studies

show

that

Lxn

deficient

mice

displayed

a

hyperproliferative hematopoiesis in BM, and there are increased numbers of LSK
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cells in Lxn-/- PB. Two hypothesis may explain these findings: 1) The HSPC
population expands due to increased proliferation and/or decreased apoptotic
activity. Excessive HSPCs egress into the blood circulation to maintain the
homeostasis. 2) A compromised HSPC retention capacity induces increased
mobilization. Thus, weak interactions between HSPCs and stromal cells enable
HPSCs to readily egress into the blood circulation under homeostasis, or after
the administration of mobilization cytokines. As mentioned previously, Lxn-/mice exhibit a hyperproliferative hematopoiesis in the BM, implying that the upregulation of LSK population in PB is induced by homeostatic machinery.
However, these findings are not conclusive because they do not rule out the
influence from the microenvironmental niche cells.
To further explore the effects of Lxn on HSPC retention capacity in the BM,
we used G-CSF induced mobilization. We found that Lxn-/- mice show not only
increased mobilization proficiency, but also decreased cell retention capacities of
Lxn -/- HSPCs. Microarray experimental results indicate that the enhanced
mobilization proficiency of Lxn-/- primitive hematopoietic cells is correlated with
reduced adhesion of hematopoietic progenitor cells to stroma. Thbs-1 has been
identified as a potential target of Lxn in regulating enhanced mobilization in Lxn-/mice. The expression level of Thbs-1 gradually decreases along the
hematopoietic differentiation hierarchy in parallel with Lxn expression. I am
currently ectopically overexpressing Thbs-1 in primitive hematopoietic cells. The
next logical step for this project is to study the mobilization proficiency and
retention capacity of HSPCs overexpressing Thbs-1 both in vivo and in vitro.
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4.3 Methods
4.3.1 Animals

C57BL/6 mice (B6) (8-16 weeks) were purchased from The Jackson
Laboratory (Bar Harbor, ME). Lxn constitutive knockout mice were generated by
Taconic/Artemis (Germantown, NY) and used at a young age (8-16 weeks). All
animals were housed in the animal facilities of the University of Kentucky under
pathogen-free conditions according to NIH-mandated guidelines for animal
welfare. They were fed with food and water ad libitum.
4.3.2 Hematopoietic cell identification and isolation

Bone marrow cells were flushed from the femora and tibiae using a 1 ml
syringe and 22G needle into Hanks balanced salt solution (HBSS) with 2% fetal
bovine serum (FBS). Progenitor cells were discriminated from stem cells by the
lack of cell surface antigens characteristic of cells committed to individual
lineages. Antibodies against these antigens include CD5 and CD8a, B220, Mac1, Gr-1, and Ter119 are biotinylated. Strepavidin secondary antibody was used to
detect lineage negative cells. To further purify primitive cells, the stem cell
markers Sca-1 and c-Kit were incorporated into the staining procedure.

The

multi-potent progenitor (MPP) cells are identified by immunophenotyping as cells
negative for Lineage markers, but positive for Sca-1, c-Kit, Flt-3 and CD34. Dead
cells were excluded by propidium iodide (PI) that stains exposed double-strand
DNA. All monoclonal antibodies were purchased from eBioscience (San Diego,
CA), Biolegend (San Diego, CA), or DB pharmingen (San Jose, CA).
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4.3.3 Cell analysis and sorting

BM cells were analyzed and sorted on a FacsAria II flow cytometer
(Becton Dickinson, Franklin Lakes, NJ). Cells were sorted into phosphate
buffered saline (PBS) with 0.5% FBS for further use. Each experimental group
was sorted independently. Flow cytometry and FACS data were analyzed using
FlowJo software (Tree star, Ashland, OR).
4.3.4 Mobilization assay

To mobilize HSPCs to blood circulation, recombinant human G-CSF
(rhuG-CSF) (Amgen Biologicals, Thousand Oaks, CA) was intra-peritoneally (i. p.)
injected at 100 ug/kg daily for 5 days at a concentration of 12.5 ug/mL in PBS/0.1%
BSA. HSPC frequency in PB, BM and spleen was measured by CFC assay and
flow cytometry.
4.3.5 Colony forming cell (CFC) assay

Methylcellulose-based culture media was obtained with Complete
MethoCult Media (Stem Cell Technologies, Vancouver, Canada) containing
cytokines including stem cell factor (SCF), IL-3 and IL-6 cytokines. For this assay,
10 ul PB or 1 x 105 spleen cells in 100 µL HBSS were thoroughly admixed with 1
mL complete MethoCult media, plated into 6-well petri-dish and incubated at
37°C. Wells of triplicate cultures were counted on day 7 for PB and on day 8 or
14 for spleen to quantify lineage-specific colonies.
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4.3.6 HPC adhesion assay

As in the CAFC assay, FBMD-1 stromal cells were pre-seeded in 96-well
tissue culture-treated plates. After FBMD-1 cell monolayers reached confluence
(7-10 days post plating), whole BM cells were plated at doses of 400, 800, 1600,
3200, 6400, 12800, 25600 and 51200 per well with CAFC medium. To assess the
progenitor cell adhesion, 2 hours later non-adherent cells were washed by gently
aspirating the medium up and down with a micropipet, and the cells were then
removed. Fresh medium was then added to each well. The frequency of total
HPCs and adherent HPCs was assessed by the appearance of cobblestoneareas in each well on day 7. The difference between the number of the
cobblestones formed in unmanipulated wells and washed wells provided an
index of the strength of adhesion between the CAFCs and the FBMD-1 stromal
cells. The adhesion of HPCs was calculated by normalizing the numbers of
cobblestones formed in washed wells to the unmanipulated wells (%).
4.3.6 Microarray analysis

As described in Chapter 2, microarray experiments were performed on
fresh BM multipotent progenitor cells obtained from three wild type and three
Lxn-/- biological samples using Affymetrix Gene Chip MoGene-1_0-st-v1 arrays.
Data were normalized based on the RMA method131. To study pathway changes
in response to the genomic alteration, in this chapter we performed the gene set
enrichment analysis (GSEA) based on the GSEA Java desktop software
application, using the same microarray experiment data132. Genes were pre-
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ranked based on the absolute values of the test statistics calculated using the
LIMMA package in R/Bioconductor. We investigated all the pathways in the
KEGG database. Five enriched pathways were identified with false discovery
rate of less than 25%. Individual genes that were differentially expressed were
identified with a p-value less than 0.01.
4.3.7 Statistics

Statistical significance between means was determined by a two-way
Student t test.
4.4 Results
4.4.1 Mobilization of HSPCs is increased in Lxn-/- mice

Granulocyte colony-stimulating factor (G-CSF) is widely used in clinical
practice to stimulate the movement of stem and progenitor cells from the BM into
peripheral blood circulation. In this study, we used G-CSF induced mobilization to
explore the effect of Lxn in hematopoietic cell function. Lxn-/- mice and B6 mice
were given G-CSF daily for 5 days. Flow cytometric analysis combined with cell
surface marker antibodies were used to identify phenotypic HSPCs in PB after GCSF administration. HPCs were identified by immunophenotyping as cells
negative for lineage markers and Sca-1 antigen, and positive for c-Kit receptors
(Lin-Sca-1-c-Kit+), whereas HSCs were negative for lineage markers and positive
for Sca-1 and c-Kit receptors (Lin-Sca-1+c-Kit+) (Fig. 4.1A). HSPCs were negative
for lineage markers and positive c-Kit receptors (Lin-c-Kit+) (Fig. 4.1A). Using

91

these parameters, we demonstrated that the mobilization of HSPCs in Lxn-/mice was significantly increased (2-fold) after G-CSF administration (Fig. 4.1A
and B). Within the HSPC population, the number of HPCs in PB was increased
3.5-fold, whereas the number of HSCs in PB remained intact (Fig. 4.1A and B).
These data showed that the mobilization of HPC from BM into PB was increased
by loss of Lxn expression in hematopoietic cells.
Colony forming cell (CFC) assay is an in vitro assay specifically measuring
the number of functional hematopoietic progenitor cells. Next we used CFC
assays to determine the HPC mobilization in both Lxn-/- and B6 animals. Blood
was collected and analyzed on day 6 and the frequency of HPCs in PB was
measured by the CFC assay. Before mobilization, PB CFC frequency in Lxn-/mice is 30% more than the frequency in wild type B6 mice (Fig. 4.2A). G-CSF
mobilized 15 and 13-fold more HPCs to PB in Lxn-/- and B6 mice respectively,
compared to unmobilized cells (Fig. 4.2A). After mobilization, the frequency of
CFC in the PB of Lxn-/- mice showed an increased trend compared to the
frequency of CFCs in the PB of B6 mice, however, it did not reach the statistical
difference (Fig. 4.2A).
G-CSF administration not only leads to the redistribution of primitive
hematopoietic cells from the BM to peripheral blood, but also induces their
mobilization to spleen. Thus, we studied the frequency of CFCs in the spleens of
Lxn-/- and B6 mice before and after G-CSF administration. Before mobilization,
Lxn-/- mice showed a 3-fold increase in CFC frequency in spleen compared to
wild type B6 mice (Fig. 4.2B). Post mobilization, Lxn-/- spleen CFC frequency
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was increased 10-fold over pre-mobilization frequency, whereas B6 mobilization
frequency was increased 25-fold (Fig. 4.2B). Mobilized Lxn-/- mice also showed
an increased trend in CFC frequency in spleen, but which was not significant,
compared to mobilized B6 animals (Fig. 4.2B).
In this set of experiments, we found more HPCs (measured by CFC) in
Lxn-/- spleen and PB compared to B6 in untreated animals (Fig. 4.2A and B).
These data indicate that loss of Lxn could enhance the mobilization to PB and
spleen in HPCs under homeostatic conditions. However, the frequencies of CFC
in the PB and spleen of Lxn-/- mice showed increased trends but with no
significant difference when compared to B6 mice. These findings were
inconsistent with increased phenotypic HSPCs in Lxn-/- mice identified by flow
cytometry (Fig. 4.1A and B). This may due to the sample pool size used in these
experiments. In the future, we will repeat the CFC assays with more Lxn-/- and
B6 animals to elucidate the functional progenitor cell numbers in PB and spleen.
4.4.2 Loss of Lxn impaired HSPCs adhesion to stromal cells

We next studied the adhesive properties of Lxn-/- HSPCs by directly
measuring the adhesion of HSPCs to a bone marrow-derived stromal cells
(FBMD-1) using the adhesion assay-a modified cobblestone-area forming cell
(CAFC) assay. The CAFC assay is a well-established in vitro assay to measure
HSPC activity. In this assay, stromal cells (FBMD-1 cells) were plated in a 94-well
plate and allowed to grow to confluency. BM cells were plated in each well in
limiting dilutions, and later scored for the presence of cobblestone-areas. Unlike
in a traditional CAFC assay, non-adherent HSPCs were washed off 2 hours post
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plating onto the stromal cell (Fig. 4.3A). The frequency of adhesive HSPCs was
subsequently determined at day 7 and normalized to the frequency of HSPC in
unwashed plates. This experiment allowed us to study the ability of HSPCs to
anchor and adhere to the stroma in vitro. We performed the adhesion assay with
Lxn-/- and B6 BM cells, and found that Lxn-/- BM cells showed a 40% reduction
in the ability to adhere to stromal cells when compared to B6 compared to B6
cells (Fig. 4.3B). This result suggests that increased mobilization of HSPC may
be caused by compromised adhesive properties of BM cells in the niche.
4.4.3 Decreased levels of adhesive molecules in Lxn-/- mice

The adhesion and detachment of HSPCs from the stroma were tightly
regulated by adhesion molecule activities. To study whether changes in
adhesion/mobilization efficiency correlate with changes in adhesive molecule
expression, we conducted microarray experiments on MPP cells obtained from
Lxn-/- mice and B6 (see in Chapter 2). Gene set enrichment analysis (GSEA)
identified five enriched pathways that were significantly dysregulated (Tab. 4.1).
Among these five pathways, cell-to-cell communication and ECM-receptor
interaction pathways are involved in regulating HSPC adhesion/mobilization. The
expression levels of most adhesive molecules were down-regulated, indicating
that the enhanced mobilization efficiency of hematopoietic cells from Lxn-/- mice
may be caused by reduced adhesion properties of hematopoietic progenitor cells
to stroma (Tab. 4.2 and 3). In previous studies, the Thbs-1 gene was identified as
one of the most down-regulated adhesion-related molecules in our microarray
studies. Its expression level was decreased 4-fold in Lxn-/- hematopoietic multi94

potent progenitor populations (not shown). In previous studies, we tested Thbs-1
expression at the levels of transcript (quantitative real-time PCR) in
hematopoietic cells and found the thbs-1 expression gradually decreased along
the hematopoietic differentiation hierarchy, in parallel with Lxn expression (as in
Chapter 2). To further study the in vivo role of Thbs-1 in regulating increased
mobilization in Lxn-/- mice, Thbs-1 will be overepxressed in primitive
hematopoietic cells and the retention properties of cells overexpressing Thbs-1
will be tested
4.5 Discussion
HSCs change locations several times during embryonic development,
shifting from the yolk sac and Aorta-gonad-mesonephros (AGM) region to the
fetal liver, and finally to the BM19. In adult life, HSCs remain dynamic, trafficking
between BM niches and extramedullary sites such as spleen, liver and blood in
response to various stresses20. The periodic and diurnal release of HSCs into
blood stream is an essential mechanism for regulating homeostasis, and
extramedullary hematopoiesis commonly occurs in hematopoietic disorders21.
While studying the hematopoietic system in Lxn-/- mice, we identified an
increased HSC population in the peripheral blood system. There are two possible
explanations

for

this

observation:

hyperproliferative

hematopoiesis

or

compromised HSC retention in the BM niche. We observed hyperproliferative
hematopoiesis in both the PB and BM of Lxn-/- mice. However, to our knowledge,
no studies have been performed focusing on HSC retention capacity and
mobilization in Lxn-/- mice. Here we identified a role for Lxn in regulating the
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mobilization of HSPCs, as shown by the fact that loss of Lxn enhanced
mobilization proficiency and decreased cell retention during homeostasis and
after G-CSF administration. We identified that the mobilization of HSPCs
(phenotypically identified) from BM to PB in Lxn-/- mice was significantly
increased (2-fold) compared to B6 mice after G-CSF administration (Fig. 4.1A
and B). However, the results from PB CFC assay found no significant difference
between the number of CFCs formed by PB from Lxn-/- and B6 mice after GCSF administration. This observation may be explained by the sample size. We
performed CFC experiments once with 3 biological samples in each experimental
group, which may not be adequate to show statistic difference. The person who
will carry this project will need to repeat this experiment two more time and with
more Lxn-/- and B6 animals. The other possible explanation for this observation
is that the progenitor mobilized into PB become non-functional, therefore would
not form colonies. To test the hypothesis that HSPCs lose their function in Lxn-/mice after mobilization, we can perform the CFC assay with purified phenotypic
Lxn-/- and B6 HSPCs (Lin-c-Kit+ cells). If what we hypothesized is true, there will
be less colonies formed with equal numbers of HSPCs from Lxn-/- mice than B6
mice after mobilization. Because even though flow cytometric analysis showed
more HSPCs are released to PB in Lxn-/- mice, most of progenitor cells are nonfunctional.
Many of the same adhesion molecules are expressed on both on stem
cells and stromal cells. The overlapping expressions of these molecules (that
bind to the same ligands or shared similar functions) provide redundancies in
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expression and function34-36. This strategy ensures that a minor reduction in one
or several adhesion molecules does not affect stem cell behavior and
homeostasis. However, in our studies, microarray analysis identified an extensive
list of adhesion molecules (involved in cell-to-cell and cell-to-ECM interactions)
which were universally under-expressed. It is possible that small reductions in
gene expression of many individual genes compromise HSPC retention and
promote HSPC mobilization in Lxn-/- mice133. This hypothesis explains the
observation that more HSPCs (phenotypically identified) are released into blood
circulation in Lxn-/- PB compared to B6. In clinical practice, the interactions
between stem/progenitor cells and stromal cells are disrupted by G-CSF or other
cytokines, resulting in the relocalization of HSPCs to the peripheral blood25-29. In
this study, G-CSF administration manifests the defect (a compromised HSPC
retention) and induces the release of significantly more HSPCs (phenotypically
identified) into blood circulation.
Among the adhesion molecules, thbs-1 is the most down-regulated. Its
expression level was decreased 4-fold in Lxn-/- MPP population. The thbs-1
protein is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix
interactions133, 134. It is a critical part of the stem cell niche, and is involved in
binding to other adhesion molecules such as fibrinogen, fibronectin, intergrin and
collagen10. To further study the in vivo role of thbs-1 in regulating increased
mobilization in Lxn-/- mice, we ectopically overexpressed thbs-1 in primitive
hematopoietic cells. The cells overexpressing Thbs-1 will be tested for their
retention capacity using in vitro and in vivo experiments.
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In conclusion, the loss of Lxn in hematopoietic cells enhances their
mobilization into peripheral blood system and results in a compromised retention
capacity through down-regulating the adhesion molecules which involved in cellto-cell and cell-to-ECM interactions.
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A

B

Figure 4.1 Flow cytometric analysis of mobilized HSPCs in PB of B6 and
Lxn-/- mice.
(A) and (B) Flow cytometric analysis demonstrating the numbers of Lin-Sca-1+c-Kit+
cells (HSCs), Lin-Sca-1-c-Kit+ cells (HPCs) and Lin-c-Kit+ cells (HSPCs) in the PB of
unmobilized or mobilized B6 and Lxn-/- mice (n=4 for each group). * indicated a
P<0.05 hereafter.
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A

B

Figure 4.2 Mobilization of HSPC in B6 and Lxn-/- mice measured by CFU
assay.
(A) The frequency of CFCs in 10 uL PB in unmobilized or mobilized B6 and Lxn-/mice (n=3 for each group). (B) The frequency of CFCs in spleen in unmobilized or
mobilized B6 and Lxn-/- mice (n=3 for each group).
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Figure 4.3 Adhesion capacities in HSPCs in B6 and Lxn-/- mice.
(A) Experimental design of the adhesion assay. BM cells from the unmobilized B6
and Lxn-/- mice were added to wells containing confluent feeder cells. Non-adhesive
cells were washed away after 2 hours and plates were scored at day 7. The
frequency of adherent HPCs (washed) was normalized to the initial HPC frequency
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(unwashed). (B) Percentage of adherent HPCs (the frequency of adherent HPCs
normalized to the initial HPC frequency) (n=3 for each group).
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Table 4.1 GSEA enrichment table of pathways altered in Lxn-/- MPP cells

Name
Proteasome
Cell-Communication
Neuroactive-ligand-receptor
ECM-Receptor-interaction
Cell-cycle

Size

FDR q-value

# of genes in leading
edge

18
120

0.004
0.003

14
88

222

0.003

147

80
95

0.002
0.19

44
79

List of 5 top differentially expressed pathways from Lxn-/- MPP population. The
number of genes in each pathway, number of genes in the leading edge, and
corresponding FDR q-value are listed as above.
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Table 4.2 Gene expression profile of genes in Cell-to-ECM interaction
pathways.
Gene

Contrast

Gene

Contrast

Gene

Contrast

THBS4

-1.25

GP9

-1.25

ITGB7

-1.10

COL5A2

-1.24

LAMA3

-1.15

ITGA10

1.0

COL1A2

-1.26

ITGA2

-1.25

SV2B

-1.10

COL4A6

-1.23

COL11A2

-1.11

GP1BA

-1.05

FNDC5

-1.23

ITGB6

-1.12

TNR

-1.0659

ITGA7

-1.23

SV2C

-1.11

SDC1

-1.10

THBS1

-3.44

FNDC1

-1.1

ITGA8

-1.106

SDC4

-1.25

ITGB8

-1.17

LAMA5

-1.04

LAMA1

-1.18

FNDC3A

1.12

SPP1

1.04

TNN

-1.22

COL5A3

-1.12

THBS2

-1.04

LAMB3

-1.18

LAMC3

-1.12

LAMB2

-1.03

COL4A4

-1.21

CD44

1.12

SV2A

-1.03

ITGA2B

-1.24

LAMA4

-1.10

FNDC4

-1.03

LAMC2

-1.17

TNXB

-1.13

CD47

1.02

COL11A1

-1.19

ITGA6

1.12

ITGB3

-1.02

LAMA2

-1.19

TNC

-1.13

ITGA4

-1.02

COL1A1

-1.20

COL6A2

-1.11

AGRN

1.02

COL2A1

-1.19

ITGA3

-1.12

ITGA11

-1.01

THBS3

-1.15

COL4A2

-1.10

SDC3

-1.02

COL6A3

-1.17

GP5

-1.119

ITGB5

-1.01

HMMR

1.25

ITGAV

-1.11

DAG1

-1.01

ITGA9

-1.31

LAMC1

1.1

SDC2

1.1

VWF

-1.15

ITGA1

-1.20

FN1

-1.0

HSPG2

-1.14

COL4A1

-1.10

CD36

-1.1
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Table 4.2 continues

CHAD

-1.27

COL6A1

-1.10

GP9

-1.25

COL5A1

-1.14

RELN

-1.10

VTN

-1.16

80 genes in Cell-to-ECM interaction pathway have been listed above with their
expression level altered in Lxn-/- MPP cells. Majority of the genes have been downregulated.
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Table 4.3 Gene expression profile of genes in Cell-to-Cell interaction
pathway.
Gene

Contrast

Gene

Contrast

Gene

Contrast

THBS4

-1.25

COL2A1

-1.19

GJA3

-1.11

COL5A2

-1.24

THBS3

-1.15

GJA5

-1.14

COL1A2

-1.26

COL6A3

-1.17

LAMA4

-1.10

KRT86

-1.30

VWF

-1.15

GJA10

-1.14

COL4A6

-1.23

KRT12

-1.15

TNXB

-1.13

KRT74

-1.20

CHAD

-1.27

KRT15

-1.10

THBS1

-3.44

KRT2

-1.14

ITGA6

1.12

KRT75

-1.21

COL5A1

-1.14

GJC1

-1.11

KRT31

-1.18

GJD2

-1.13

TNC

-1.13

KRT28

-1.2

VTN

-1.16

LMNB1

1.1

KRT24

-1.23

GJB6

-1.15

COL6A2

-1.1

KRT84

-1.24

KRT40

-1.14

KRT35

-1.11

GJA8

-1.18

KRT78

-1.12

KRT34

-1.10

LAMA1

-1.18

LAMA3

-1.15

KRT20

-1.13

TNN

-1.22

KRT23

-1.20

GJB3

-1.13

KRT9

-1.22

KRT33B

-1.15

GJD4

-1.10

DES

-1.18

COL11A2

-1.11

COL4A2

-1.10

GJB1

-1.18

KRT4

-1.15

KRT14

-1.12

LAMB3

-1.18

KRT77

-1.13

GJC2

-1.10

COL4A4

-1.21

KRT76

-1.15

KRT17

-1.10

LAMC2

-1.17

KRT19

-1.15

KRT1

-1.10

COL11A1

-1.19

GJD3

-1.11

KRT33A

-1.10

LAMA2

-1.191

KRT13

-1.14

KRT82

-1.10

COL1A1

-1.12

KRT18

-1.24

LAMC1

1.10
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table 4.3 continues

DSC2
KRT36
GJB5

-1.18
-1.17
-1.10

COL5A3
GJA4
DSC1

-1.12
-1.10
-1.10

COL4A1
DSG4
LMNA

10
-1.10
1.10

RELN

-1.10

PRPH

-1.10

KRT83

-1.04

KRT72

-1.10

KRT39

-1.10

KRT6B

1.04

GJB4

-1.10

KRT25

1.05

KRT73

-1.02

VIM

1.10

TNR

-1.10

DSC3

-1.02

KRT32

-1.10

KRT8

1.05

NES

-1.02

IBSP

-1.10

KRT79

-1.04

ACTB

1.01

DSG2

-1.12

KRT27

-1.04

KRT5

-1.01

COL3A1

-1.10

LAMA5

-1.04

KRT6A

1.003

GJA1

1.10

SPP1

1.04

FN1

-1.004

COMP

-1.10

KRT7

-1.04

KRT16

1.003

LMNB2

1.10

THBS2

-1.04

KRT71

-1.001

DSG3

-1.10

LAMB2

-1.03

KRT10

-1.00009

120 genes in Cell-to-Cell communication and interaction pathway have been listed
above with their expression level altered in Lxn-/- MPP cells. Majority of the genes
have been down-regulated.
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CHAPTER 5: Latexin is Down-regulated in Hematopoietic Malignancies and
Restoration of Expression Inhibits Lymphoma Growth

5.1 Abstract
Latexin is a negative regulator of hematopoietic stem cell number in mice.
Its dysregulated expression in other tumors led us to hypothesize that latexin
may have tumor suppressor properties in hematological malignancies. We found
that latexin was down-regulated in a variety of leukemia and lymphoma cell lines
as well as in CD34+ cells from the blood and marrow of patients with these
malignancies.

5-aza-2’-deoxycytodine

treatment

and

bisulfite

sequencing

revealed hypermethylation of latexin promoter in tumor cells. Retrovirusmediated latexin overexpression in A20 mouse lymphoma cells inhibited their in
vitro growth by 16 fold and in vivo tumor volume by 2 fold. Latexin caused growth
inhibition of lymphoma cells by significantly increasing apoptosis through the
down-regulation of anti-apoptotic genes Bcl-2 and Pim-2. The molecular
mechanism underlying latexin-mediated tumor inhibition was not through its
canonical carboxypeptidase inhibitor activity. These results are consistent with a
tumor suppressor role for latexin and suggest that latexin may have clinical
efficacy in the treatment of malignancies.
5.2 Introduction
Both solid and liquid tumors are now understood to originate from the
malignant transformation of resident adult stem and progenitor cells135,
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.

Nowhere is this paradigm better established than in leukemia, yet events causing
neoplastic conversion remain poorly understood137. We identified latexin (Lxn) as
a novel, homeostatic regulator of the size of the hematopoietic stem cell
population in mice93. The stem cell pool size was inversely related to quantitative
Lxn expression at both the levels of transcript and protein. We found that
population size was influenced by Lxn in a stem cell-autonomous manner, and
acting through the concerted mechanisms of self-renewal and apoptosis, which
were decreased and increased, respectively, by Lxn abundance93. Thus, Lxn acts
as a brake on the expansion of stem cell population. Unrestrained stem cell
expansion carries with it the risk of mutations, genomic instability and
carcinogenesis. We therefore hypothesized that Lxn expression patterns in stem
and progenitor cells may act as a tumor suppressor by inhibiting stem and
progenitor cell proliferation, influencing the crucial steps toward malignancy.
Lxn was primarily studied in the nervous system, involving the
specification of cortical brain regions during development89, 138-141, as well as the
speed of nerve transmission in adult peripheral nervous systems90. Lxn was
found to be involved in the inflammatory response in macrophages owing to its
paired cystatin-like domains142. It was detected in mast cells associated with a
unique type of intracellular granule distinct from histamine-containing secretory
granules and lysosomes91. Lxn has about 30% sequence homology, but much
greater structural homology, with tazarotene-induced gene 1 (TIG1) (or retinoic
acid receptor responder 1, RARRES1), whose expression was down-regulated in
an extensive list of tumor types in humans106, 142-145. Lxn and TIG1 are closely
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linked genetically and may represent members of a family of functionally related
genes. Moreover, Lxn was reported to be a TNF-responsive gene in human
papillovirus-infected keratinocytes, suggesting that it may contribute to TNFmediated suppression of cervical cancer development146. A recent report
revealed that Lxn was down-regulated in patients with gastric carcinomas, and
overexpression or knockdown of Lxn inhibited or stimulated tumor growth
respectively147. Decreased or absent Lxn expression was observed in several
human leukemia and lymphoma cell lines148, as well as in malignant melanoma
patients149. However, there is still lack of direct evidence for the cause-effect
relationship between Lxn and hematopoietic malignancy.
Gene silencing, especially of tumor suppressors, and inappropriate gene
activation, especially of oncogenes, are common themes in carcinogenesis150.
Both often occur through aberrant DNA methylation that is accentuated during
aging151-156. A CpG-enriched region was identified in Lxn promoter and its
hypermethylation was found in a variety of human gastric carcinoma cell lines147.
Promoter hypermethylation of TIG1 was also associated with its silencing in
tumor cells

106, 145

. However, it is not known whether Lxn expression is regulated

by promoter methylation in hematopoietic malignancy.
Molecular mechanisms underlying the role of Lxn in regulating
hematopoiesis

has

not

been

determined

yet.

Lxn

protein

binds

to

carboxypeptidase A (Cpa) and inhibits its enzymatic activity, indicating that Lxn
regulates protein degradation and metabolism148. Lxn was highly expressed in
mast cells and its expression was further enhanced by LPS, indicating its
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potential function in inflammation142. Proteomic analysis on Lxn knock-out
hematopoietic cells revealed that Lxn deletion reduced the abundance of multiple
cellular proteins, especially those involving cell-stroma interaction, such as Ncadherin, Tie2, and Roundabout 4148. Ectopic expression of Lxn in gastric cancer
cell lines led to the differential expressions of several cancer-related genes,
including Maspin, WFDC1, SLPI, S100P, and PDGEFB

147

, although none of

them are overlapped with previously mentioned proteomic results. A recent study
revealed ATP/GTP binding protein-like 2 (AGBL2) as a novel binding partner of
TIG1. The interaction between TIG1 and AGBL2 regulates the microtubule
tyrosination cycle, which is implicated in tumorigenesis, stem cell differentiation
and development157. Lxn thus may have the similar mechanisms as TIG1 to
regulate hematopoiesis.
Here, we provide evidence obtained from a variety of lymphoma and
leukemia cell lines, as well as from primary cells from patients with these
diseases, that Lxn expression is almost universally absent or significantly
reduced from that of normal stem and progenitor cells. Moreover, treatment with
a de-methylating agent at least partially restores Lxn expression in a variety of
tumor cell lines, and methylation level of the CpG island in the Lxn promoter
region is inversely associated with its expression. Perhaps most importantly, we
show that when Lxn expression was re-initiated ectopically in two lymphoma cell
lines using a retroviral expression vector, their growth, both in vitro and in vivo,
was significantly blunted. We further show that Lxn inhibits lymphoma cell growth
by significantly increasing apoptosis through the down-regulation of anti-
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apoptotic genes and that its anti-tumor activity is mediated via mechanisms
unique from its canonical inhibition of carboxypeptidase A. These results
demonstrate that Lxn plays a functional role in tumor cell growth and introduces
an unexplored pathway potentially important to cancer treatment in patients.
5.3 Material and Methods
5.3.1 Animal

Young 8-to 12- week old female C57BL/6 (B6) and 7-week old female
BALB/c mice were purchased from the Jackson Laboratories (Bar Harbor, ME).
Mice were kept in the animal facilities of the University of Kentucky under
pathogen-free conditions according to NIH-mandated guidelines for animal
welfare. They were fed with acidified water and food ad libitum. All animal work
in this study was approved by Institutional Animal Care and Use committee
(IACUC) at the University of Kentucky (Identification number: 2010-0753)
5.3.2 Leukemia cell lines

Nine human leukemic cell lines (K562, Molt4, CCRF-CEM, J45.01, Jurkat,
U937, HL-60, KG-1 and SupB15) and two mouse lymphoma cell lines (WEHI-231
and A20) were included in our study. Human leukemic cell lines were purchased
from American Type Culture Collection (ATCC) (Manassas, VA). Mouse
lymphoma cell lines are gifts from Dr. Bondada
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. The leukemia cell lines were

maintained in IMDM supplemented with either 10% (K562) or 20% (KG-1, HL-60
and Sup-B15) fetal bovine serum (FBS), or RPMI medium with 10% FBS, 10mM
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Hepes

(Molt4,

CCRF-CEM,

J45.01,

Jurkat

and

U937),

0.05mM

2-

mecaptoethanol, 80 U/mL penicillin, and 80mg/mL streptomycin. The cells were
incubated in a humidified atmosphere of 5% CO2 in air at 37°C.
5.3.3 Isolation of CD34+ cells

Primary AML cells were obtained from the peripheral blood and bone
marrow of patients at the Markey Cancer Center and Northwestern University.
Normal bone marrow was obtained as discarded material following pathologic
analysis, surgical marrow harvest, or from the National Disease Research
Interchange (NDRI). CB was obtained from patients at the University of Kentucky
Obstetrics Department or from the NDRI. All tissues were obtained with the
approval of the respective institutional review boards and appropriate informed
consent (confirmation number is 11-0315-F3R from University of Kentucky).
Some samples were collected from Northwestern University and transferred to
University of Illinois at Urbana-Champaign with approval of Material Transfer
Agreement (MTA). We processed 9 normal and 9 leukemia and lymphoma
samples, the age and disease type of each sample are described in the figure
5.5 legends. Marrow and blood cells were depleted of erythrocytes by
suspending in 150 mM NH4Cl plus 10 mM NaHCO3 for 5 minutes, followed by 2
washes with phosphate-buffered saline (PBS). Blood cells were subjected to
Ficoll-Paque (Pharmacia Biotech, Piscataway, NJ) density gradient separation to
isolate the mononuclear white blood cell compartment. Resulting leukocytes from
marrow or blood were then used for immunoaffinity selection and flow cytometric
sorting. For CD34+ cell selection, the Miltenyi immunoaffinity device (VarioMACS)
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was used according to the manufacturer's instructions (Miltenyi Biotech, Auburn,
CA), and further purified by immune-staining with anti-CD34 antibodies
(Pharmingen, San Diego, CA) and sorting in a triple-laser FACSVantage flow
cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). In
some cases, leukocytes were cryopreserved at a concentration of 5 x 107
cells/mL in freezing medium consisting of Iscoves modified Dulbecco medium
(IMDM), 40% FBS, and 10% dimethyl sulfoxide (DMSO).
5.3.4 Quantitative real-time PCR

To measure the expression of Lxn in leukemic cells, quantitative real-time
PCR was performed. Identical numbers (200,000) of cells were used for total
RNA extraction using RNeasy Mini kit (QIAGEN, Valencia, CA) according to the
manufacture’s instruction. Isolated total RNA was reverse transcribed into cDNA
using random hexamers in a TaqMan® reverse transcription solution (PN
N8080234) and stored at -20ºC. In real-time PCR reactions, primer and probe
mix for LXN (human and mouse) were purchased from Applied Biosystems
(Foster

city,

CA,

USA).

TaqMan®

human

glyceraldehyde-3-phosphate

dehydrogenase (GAPDH) was served as an endogenous control to normalize
LXN expression. PCR reactions were set up according to manufacturer’s
instructions using TaqMan® universal PCR master mix (PN 4304437). Analyses
of gene expression were performed in single reporter assays in an ABI PRISM
7700 sequence detection system (PE Biosystems, Foster city, CA, USA).
RT2 Profiler Apoptosis PCR Array (PAMM-012Z, QIAGEN) was performed
according to the manufacturer's instructions. cDNAs was prepared from A20 cells
114

infected with empty or lxn expression vectors with RT2 First Strand cDNA Kit (C03, QIAGEN) and added to RT2 qPCR master mix (PA-012). The mixture was
aliquoted across the PCR array which contains 84 apoptosis-related genes.
Gene expression and quantification was performed in an ABI PRISM 7700
sequence detection system, and data was analyzed with using web-based
software (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). The
genes with more than 2-fold change in expression and showing statistically
significant (p<0.05) were chosen for candidate gene.
5.3.5 Western blots

Cell samples were lysed at a concentration of 2x107 cells/ml in a protein
lysis buffer containing: 10mM Tris pH7.5, 50mM NaCl, 30mM sodium
pyrophosphate, 50mM NaF, 5µM ZnCl2 and 1 % Triton X-100, 2.8ug/ml aprotinin
(Sigma-Aldrich; St. Louis, MO), 1mM phenylmethylsulfonyl fluoride (Sigma), 1mM
sodium vanadate (Na3VO4) 1ug/ml pepstatin, and 1µg/ml leupeptin (Oncogene
Research, MA, USA). Lysate was incubated on ice for 30 minutes, and then
centrifuged at 15,000 x g for 10 minutes to remove debris. The resulting
supernatant was then aliquoted and stored at -80°C. For Western blot, protein
lysates were thawed and mixed with running buffer and a reducing agent (Novex,
San Diego, CA, USA, per manufacturer’s instructions) and heated at 95°C for 5
minutes. Samples were then analyzed by denaturing PAGE (Novex, 10% bis-Tris
gel) using the equivalent of 4x105 cells per lane. Following electrophoresis,
samples were electro-transferred onto immunobilon-P membranes (Millipore,
Bedford, MA, USA), which were subsequently blocked and probed with
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polyclonal rabbit anti-LXN Ig-G antibody at a 1:3000 dilution. This antibody was
generated from the Lxn-specific amino acid sequence CKHNSRLPKEGQAE at
the carboxyl terminus, and was produced by Bethyl Laboratories, Inc.
(Montgomery, TX). The antibody for detection of human LXN was purchased
from Abcam Inc. (Cambridge, MA) and used at 1:2000 dilution. The antibodies for
apoptotic proteins, Bcl-2, Bcl-xl, Bax, Bad (Santa Cruz Biotechnology) were
provided by Dr. Bondada. The antibody for Pim-2 was purchased from
eBioscience (San Diego, CA). Primary antibodies were detected using alkaline
phosphatase-conjugated secondary antibodies (Santa Cruz Biotechnology) and
electro-chemifluorescent (ECF) reagent (Pharmacia Biotech) according to the
manufacturer’s instructions. Blots were visualized using a Molecular Dynamics
STORM 860 system and Imagequant Software. Following the detection and
quantification of anti-LXN antibody, immunobilon-P membrane was sequentially
stripped in 40% methanol and the buffer containing 100mm ß-mercaptoethanol, 2%
sodium dodecyl sulfate and 62.4mM Tris-HCl to remove ECF reaction product
and antibodies, respectively. The stripped membrane was re-probed with antiactin antibody (Sigma) at 1:500,000 dilution and detected as described previously.
5.3.6 Genomic bisulfite sequencing

To investigate the methylation pattern of Lxn promoter, CpG island
analysis in the upstream sequence of Lxn open reading frame. Nucleotide
sequence of Lxn in upstream region (–1000 bp) and the first 3 exons (+373bp)
was obtained from Ensembl database (www.ensembl.org) with ID number
ENSG00000079257. CpG island search using CpG island searcher website
116

(http://www.uscnorris.com/cpgislands2/cpg.aspx) showed a 252bp region (–
208bp to +44bp) in upstream of Lxn sequence enriched for CpG repeats. The
criteria of 5 CpG island is: GC content >50%, ratio of CpG to GpC > 0.6 and 200
bp of minimum length. Genomic DNAs were isolated using AquaPure Genomic
DNA kit (Bio-Rad, Hercules, CA) and modified by sodium bisulfite using EpiTect®
Bisulfite kit (QIAGEN, Valencia, CA). For the Lxn promoter methylation study, we
designed primers that could amplify a 423bp fragment in the upstream region of
Lxn

containing

CpG

island.

The

forward

primer

sequence

is

5’

GTTGGTGTTTGATAAGTATGTGG 3', and the reverse primer sequence is 5’
TTTAACCTTCTACACCTCAAACAC 3’. The annealing temperatures for primers
were 52°C for 2 minutes. Hot-start PCR with a total cycle number of 30 was used
in all PCR amplifications. Denaturation and extension cycles were maintained for
95 °C, 30 seconds and 72 °C, 1 minutes respectively. The amplified fragments
were cloned into the pCR2.1-TOPO vector using TOPO TA Cloning Kit
(Invitrogen Carlsbad, CA) and sequenced (MWG Technology) (n 3 clones for
cell line and n 8 clones for primary cells).
5.3.7 5-aza-2’-deoxycytidine treatment

To examine the correlation of promoter hypermethylation and Lxn gene
expression, the leukemia cell line, shown to have a lack or decrease of Lxn
expression, was subject to 5-aza-2’-deoxycytidine treatment. Cells were plated
with 2uM 5-aza-2’-deoxycytidine (Sigma-Aldrich; St. Louis, MO) and incubated
for 4 days. The medium and the drug were replaced every 24 hours and cells
were harvested for RNA and DNA extraction 4 days after treatment.
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5.3.8 Infection of WEHI231 and A20 cells with Lxn expression vector

Cloning of the mouse Lxn gene into Sfbeta 91 retroviral vector and
production of viral supernatant were performed exactly as described previously93.
WEHI-231 and A20 cells were infected by 10ml viral supernatant at a density of
1x106 cells per 10cm plate along with 4 µg/ml of polybrene for 48 hours. The
infected cells (GFP+ cells) were sorted and expanded in culture medium. The
expanded GFP+ population, if not used immediately, was cryopreserved at a
concentration of 1 X 107 cells/mL in freezing medium consisting of 80% fetal
bovine serum, and 20% dimethyl sulfoxide (DMSO).
5.3.9 Measurement of growth of retrovirally-transduced tumor cells

Sorted GFP+ A20 cells over expressing Lxn or Sfbeta 91 empty vector
were counted on a hemacytometer using trypan blue dye exclusion and 500,000
cells were seeded into 25cm2 tissue culture flask in 4mls media. Cells were
incubated in a humidified atmosphere of 5% CO2 in air at 37°C and subsequently
counted on days 3, 8, 12, 16 and 20. At each time point, cells were split and
maintained at a concentration of 500,000 cells per 4 ml media. The cumulative
cell number was calculated from the cell counts and the dilutions made at each
culture split. FACS analysis was also performed at each time-point to measure
the percentage of GFP+ cells. For the in vivo measurement of tumor cell growth,
various numbers (5,000; 25,000; 50,000 and 100,000) of GFP+ A20 cells over
expressing Lxn or Sfbeta 91 empty vector were injected in a 50µl bolus
subcutaneously in the shaved flank of BALB/cJ mice given 3.0 Gy of gamma
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radiation 4 hrs. prior. Lymphomas were detectable by palpation 10-12 days postinjection and all three dimensions of tumors were measured blind with calipers on
days 12, 14, 16, 19, and 21. The same individual made the measurements from
day-to-day without knowing the treatment regimen the mice received. At day 21,
host mice were euthanized, the lymphomas were excised, and single cell
suspensions were made of each to determine the fraction of tumor cells
expressing GFP.
5.3.10 Cell cycle and apoptotic analysis

The culture of GFP+ A20 cells was maintained as described above. At
each time-point, cell cycle analysis was measured by BrdU labeling using BrdU
Flow Kit (Pharmingen, San Diego, CA) according to the manufacturer’s
instruction. 10ul of BrdU solution (1mM) was added to 1x106 cells in 1 ml culture
medium and incubated for 1 hour. The cells were fixed and permeabilized by
Cytofix/Cytoperm Buffer and treated with 30ug DNase for 1 hour at 37oC. After
washing with Perm/Wash buffer, cells were stained with PE-conjugated anti-BrdU
antibody for 20 minutes at room temperature, washed and 20 ul of 7-AAD was
added. The cells were analyzed by flow cytometry on Facscan (Becton Dickinson
Immunocytometry Systems, San Jose, CA).
5.3.11 Immunohistochemstry of A20 cells treated with potato carboxypeptidase
inhibitor (PCPI)

PCI was purchased from Sigma-Aldrich Co. (St. Louis, MO). FITC labeling
of PCI was performed by using FLUOROTAGTM FITC CONJUGATION KIT
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(Sigma-Aldrich) according to manufacturer’s instruction, and was used to treat
A20 cells for fluorescence internalization assays. Cells are cultured on 22x22mm
microscope cover glasses (Fisher Scientific Co., Pittsburgh, PA) in media as
described above. Cells were fixed onto cover glasses with 1:1 methanol:acetic
acid and washed 3 times by PBS. Cells were incubated with FITC-conjugated
PCI at a concentration of 30ug/ml at 37oC for 30 minutes, washed and stained
with phycoerythrin (PE)-conjugated B220 and DAPI. The cover glass coated with
A20 cell monolayer was flipped immediately and sealed onto glass slide. The
image was taken with a Zeiss Axiovert- 200 microscope using a high-resolution
Zeiss digital camera (Carl Zeiss Inc., Thornwood, NY)
5.3.12 Culture of A20 cells with potato carboxypeptidase inhibitor

To determine the effects of PCPI on A20 cell growth, A20 cells were
seeded at a density of 6x105/ well in 6-well plates, cultured overnight before the
addition of 0, 5, 15, 30 or 60ug/ml PCI. The cells were fed every 2 days with
fresh medium (as above) containing the respective concentration of PCI, and
viable cells were counted on a hemacytometer using trypan blue dye exclusion.
Cells were split according to cell population size to maintain a cell concentration
of 2-5 x 106/ml and cultures were maintained for 12 days. The cumulative cell
number was calculated from the cell counts and the dilutions made at each
culture split.
5.3.13 Statistical analysis

Data were analyzed by either student t-test assuming unequal variance
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with P < 0.05 (two-tail), or a one-way ANOVA.
5.4 Results
5.4.1 Loss of Lxn expression in malignant cells

We first determined Lxn mRNA abundance in tumor cell lines by
quantitative real-time PCR (Fig. 5.1A). Compared with normal primitive
hematopoietic cells, Lxn mRNA expression was completely absent in a majority
of tested leukemic lines, including K562, Molt4, CRF-CEM, J45.01, Jurkat and
U937, and was significantly diminished in HL-60, KG-1 and SupB15 cell lines.
LXN protein expression was also tested in all samples using Western blotting
and nearly identical results were obtained in tested cell lines (Fig. 5.1B). Our
results are consistent with those previously reported148 and include additional
leukemia and lymphoma cell lines.
5.4.2 Aberrant promoter hypermethylation of Lxn in hematopoietic

malignancy
To assess whether the loss or decrease of Lxn expression in malignant cell lines
resulted from promoter hypermethylation, methylation of the 5’ CpG island of Lxn
gene surrounding its transcriptional start site was determined by genomic bisulfite
sequencing. The CpG island spans from within the canonical 5’ promoter (-208nt) to
the transcription start site (+1nt), and extends through the entire first exon (+44nt).
There are 15 CpG dinucleotides within this region (Fig. 5.2A). The CpG island
identified here is not exactly same as the one reported previously, this may be due to
the different criteria we used for defining this region. Figure 2B depicts the
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quantitative variation in methylation for each CpG site among nine tumor cell lines.
Almost complete methylation was seen in J45.01, U937, Jurkat, Molt4 and CCRFCEM (>90%) lines, which commensurately showed an absence of Lxn expression.
Scattered methylated CpG sites were found in K562, KG-1 and SupB15 lines, which
were linked to the weak expression of Lxn. Surprisingly, although HL-60 had very low
Lxn expression, we found that none of the CpG sites were methylated. This is
probably due to other epigenetic mechanisms, such as histone deacetylation of
latexin promoter in HL 60 cells
5.4.3 Reactivation of Lxn expression with demethylation reagent treatment

To test the hypothesis that Lxn promoter hypermethylation might be
involved in the loss of expression in leukemia and lymphoma cell lines, we
studied the effect of 5-aza-2’-deoxycytidine, a DNA demethylating reagent, on
Lxn expression (Fig. 5.2C). After treatment with 2 uM 5-aza-2’-deoxycytidine for 4
days, Lxn gene expression was reactivated in cell lines completely lacking Lxn
expression prior to treatment (K562, Molt4, CCRF-CEM, J45.01, Jurkat and
U937), and was significantly up-regulated in HL-60, KG-1 and SupB15 lines. The
up-regulation of Lxn by 5-aza-2’-deoxycytidine in HL60 cells, which shows no
hypermethylation of CpG sties (Fig. 5.2B), might be because the demethylation
of other DNA sequences induces chromatin remodeling, thus exposing Lxn
promoter for the transcriptional initiation.
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5.4.4 Suppression of growth of mouse lymphoma cell lines in vitro and in vivo
following ectopic Lxn expression

To determine a correlative or causative relationship between Lxn
expression and tumor development, we next asked whether or not the reinitiation of Lxn expression affected the growth rate of malignant cells in vitro and
in vivo. To that end, we ectopically expressed Lxn, using a retroviral expression
vector containing green fluorescent protein (GFP) marker, in the mouse BALB/cderived A20 B lymphoma cell line, which lacks Lxn expression (Fig. 5.3C). The
controls are A20 cells either un-infected or infected with empty vector. The GFP
positive A20 cells were purified by flow cytometric cell sorting, and their growth
was determined in vitro and in vivo.
Fig. 5.3 shows the potent effects of Lxn expression on inhibiting tumor
growth in vitro and in vivo. Fig. 5.3A shows that cultures of A20 cells infected with
the Lxn expression vector contained only about half the number of cells at day 3
as compared to A20 cells infected with the control (empty) vector or uninfected
control cells (A20 control). The growth suppression by Lxn overexpression was
exponentially amplified during subsequent days of culture and by day 20 nearly
16 fold less tumor cells were present in Lxn-overexpressing group than in control
cultures (right panel). Fig. 5.3B shows that the fraction of GFP+ cells remained at
90-100% throughout the 20 days of culture in both the Lxn vector- or control
vector-infected cells. Fig. 5.3C shows that at day 20 of culture neither uninfected
A20 cells nor A20 cells infected with the control (empty) vector expressed
detectable Lxn protein, whereas in the Western blot a strong Lxn band was
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evident in lysate of cells infected with the Lxn vector (upper band). LXN protein
level at day 0 of culture in these cells is nearly identical to that at day 20 (data not
shown). In a separate series of experiments, we have found a similar growth
reduction in vitro when Lxn was ectopically expressed in WEHI231 lymphoma
cells (data not shown).
Fig. 5.3D shows a compilation of two independent experiments in which
ectopic Lxn expression suppressed the growth of A20 cell in vivo. 100,000 GFP+
A20 cells infected with either the Lxn expression vector or the GFP only control
vector, or uninfected A20 cells, were injected subcutaneously into the flanks of
BALB/c mice. Beginning at day 12 when tumors were first palpable, the Lxnexpressing cells caused significantly smaller tumors (filled circles; P<0.005). By
day 21 when the experiments were terminated, the tumors in the Lxn vectorinjected group averaged only 40% of the volume of tumors in the other two
control groups (P<0.05, n=12 in each group). At day 21, we determined the
fraction of tumor cells expressing GFP and Fig. 5.3F shows that virtually all of the
tumor cells in the Lxn and control vector groups were GFP+. More to the point,
Western blots confirmed strong expression of Lxn as in the cells analyzed after
20 days in culture (Fig. 5.3C). Thus, the reduction in tumor growth was due to
durable Lxn expression in the tumor cells themselves.
To explore the effects of cell dose on tumor size and latency before being
palpable, we ejected graded doses of Lxn-expressing or control A20 cells (Fig.
5.3E) to BALB/c recipient (n=4/group). At the 5,000 and 25,000 inoculum sizes,
the Lxn-expressing cells not only resulted in more impressive suppression of the
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size of tumors than with the 100,000 cell inoculum in Fig. 5.3D, but resulted in
delayed onset of measurable-sized tumors. At day 21, the reduction in tumor size
caused by ectopic Lxn expression was 83% and 63% at the 5,000 and 25,000
cell doses, respectively. Host animals were necropsied for evidence of gross
metastases to spleen, thymus and liver. No evident tumors were found in any of
the treatment groups. Similarly, flow cytometry detected no GFP+ cells in these
anatomical sites (data not shown).
5.4.5 Lxn inhibits tumor cell growth through increasing apoptosis but not via
its canonical function

As we previously reported in our normal hematopoietic stem cell studies,
high Lxn expression is associated with increased apoptosis and decreased
proliferation. To determine if these mechanisms were applied to our results with
tumor cells, we next measured these two parameters in vector-infected A20 cells
throughout 21 days of culture. As shown in Fig. 5.4A, flow cytometric analysis of
cells stained with BrdU and 7AAD allows for the discrimination of cell subsets
that are apoptotic (A), necrotic (N) or reside in G0/G1, S and G2/M phase of cell
cycle. By day 5 of culture, 10 fold more Lxn-expressing tumor cells were
undergoing apoptosis than control cells (10.6% vs 1%). No significant differences
in the proliferation and the numbers of necrotic cells were observed between
Lxn-overexpressing and control cells (data not shown). These results point to
apoptosis as the major cellular mechanism in Lxn-mediated tumor suppression.
We next investigated the molecular mechanisms underlying Lxn-induced
apoptosis. We performed apoptosis pathway-specific PCR arrays in A20 cells
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infected with either empty or Lxn-expressing vectors. We found that 17 out of 84
apoptosis-related genes were differentially expressed in Lxn-overexpressing cells,
and majority of them (15 genes) were down-regulated (data not shown). We
specifically examined several well-known apoptotic genes, including Bcl-2, Pim-2,
Bcl-xl, Bax, and Bad, and plotted their expression in Fig. 5.4B. Two anti-apoptotic
genes, Bcl-2 and Pim-2, were down-regulated by at least 3-fold in Lxnoverexpressing cells (left panel) as compared to the control, whereas proapoptotic genes, including Bax and Bad, did not show any change in their mRNA
levels. Western blots of these proteins observed the similar reduction in Bcl-2
and Pim-2 (all three isoforms) but not in Bcl-xl, Bax and Bad in Lxnoverexpressing A20 cells (right panel), which is consistent with PCR array result.
Thus our data indicate that Lxn-induced apoptosis in A20 cells is mainly through
the down-regulation of anti-apoptotic regulators, such as Bcl-2 and Pim-2.
A well-known function of Lxn is its role as the sole carboxypeptidase A
(CPA) inhibitor in mammalian cells. There are six Cpa genes (1-6) in this family.
In order to test whether or not the suppressive effect of ectopic Lxn expression
on the growth of A20 and WEHI231 cells was due to its canonical inhibitory
activity, we carried out the following experiments. We first determined which Cpa
genes are enriched in hematopoietic stem/progenitor cells. By searching our
gene expression profile of hematopoietic stem/progenitor cells (unpublished
data), we found that Cpa3 is the only gene highly expressed in hematopoietic
cells (Tab. 5.1).

Next, we tested Cpa3 expression in A20 cells that were

uninfected, or infected with empty or Lxn expression vectors, and found that it
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was not expressed in any type of these cells (Fig. 5.6). Last, we treated A20 and
WEHI cells with potato carboxypeptidase A inhibitor (PCPI), a 39 amino acid
protein which strongly inhibits mammalian CPA, at a series of concentrations
ranging from 5 to 60ug/ml of culture medium. As seen in Fig. 5.4C, none of the
concentrations had any effect on the growth patterns of the tumor lines, despite
the continuous presence of PCPI for 12 days of culture. To rule out the possibility
that PCPI failed to inhibit tumor growth because it did not enter the cells, we used
fluorescein isothyiocyanate (FITC) to label PCPI in cells. Fig. 5.4D shows A20
cells following a 30 min incubation with labeled PCPI (30ug/ml of culture
medium). The three-color micrograph shows PCPI in green (FITC), the nucleus in
blue (DAPI), and the B220 lymphoid cell surface marker in red (phycoerythrin,
PE). It is apparent that PCPI is plentiful in the cytosol but is not found in the
nucleus. The doses of PCPI chosen for the above experiments were taken
directly from a study in which the inhibitor was shown to inhibit the growth of
pancreatic adenocarcinoma cells by directly interfering with the epidermal growth
factor signaling pathway159. Maximal growth inhibition was achieved at 3050ug/ml. Thus, the mechanisms by which Lxn regulates both stem cell population
size and lymphoma growth inhibition reside in a novel pathway involving
apoptosis.
5.4.6 Down-regulation of Lxn in primary leukemia and lymphoma cells

Based on the strong evidence for the tumor suppressive function of Lxn in
leukemia and lymphoma cell lines, we asked whether or not Lxn expression is
altered in primary cells derived from patients with malignancies. We isolated
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stem/progenitor-enriched CD34+ cells from bone marrow and blood cells in
lymphoma and leukemia patients, as well as in normal donors. The patients
included those with acute myeloid leukemia (AML), T cell pro-lymphocytic
leukemia (T-PLL), plasma cell leukemia (PCL), acute T cell lymphoma (ATLL)
and acute lymphoid leukemia (ALL, preB phenotype). The normal CD34+ cell
samples were derived from cord blood (CB) and young (31 and 35 years) and old
(85 and 97 years) adults. Lxn mRNA expression, quantified by real-time PCR,
was decreased by at least two-thirds in primary malignant CD34+ cells (Fig.
5.5A). Quantification of LXN in CD34+ cells of all human normal and leukemic
samples compiled to date is plotted in Fig. 5.5B. The result shows a significant
decrease of LXN protein expression in malignant cells (P=0.03) even though Lxn
expression at the protein level is more variable than that at the mRNA level. Two
additional old samples in the normal control group contribute to this variation,
which is consistent with the report that the number and functionality of HSCs in
old individuals, perhaps stem cell regulatory gene(s), showed more dramatic
variations as compared to their young counterparts160. In summary, these data
indicate that Lxn dysregulation may be involved in human hematological
malignancies. In the future study, it will be interesting to examine the expression
of two anti-apoptotic genes, Bcl-2 and Pim-2, in patient samples to see whether
or not they are up-regulated.
5.5 Discussion
Recently we found that Lxn is a natural regulator of hematopoietic stem
cell population in mice by influencing self-renewal and apoptosis93. Lxn
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expression in stem cells is inversely proportional to the size of the population in
mice and thus acts as a negative regulator through cell-intrinsic mechanisms.
The observation that low Lxn expression in hematopoietic cells was associated
with increased replication led us to hypothesize that Lxn was down-regulated in
malignancies with high proliferative rates and/or low apoptosis.
Here, we show that Lxn is either not expressed or is strongly downregulated in a variety of leukemias and lymphomas. As a result of these findings
and close linkage structurally and genetically with TIG1, we proposed that Lxn
may similarly act as a tumor suppressor. Along with this proposal, there is
expectation that manipulation of Lxn levels in malignant cells would alter their
growth characteristics. Accordingly, two lymphoma cell lines in which Lxn
expression was absent were infected with a Lxn expression vector. In one of the
most significant findings of this study, we found that re-initiation of Lxn
expression dramatically reduced their growth in vitro and in vivo. These results
demonstrate that the level of Lxn expression is functionally related to both normal
and malignant cell growth and, if the findings are true for human tumors, may
provide an avenue for therapeutic intervention. Surprisingly, Lxn knock-out mice
did not development leukemia nor lymphoma even though their hematopoietic
stem cell pool was over-expanded and blast cells were detected in the peripheral
blood148. These results suggest that Lxn may influence the crucial step in
carcinogenesis161. It thus will be of great interest to introduce additional
carcinogenetic “hits”, such as oncogenes or alkylating agents, to Lxn knockout
stem cells to determine whether Lxn deletion will accelerate tumor development.

129

In addition, we observed that re-initiation of Lxn expression did not completely
suppress tumor cell growth, suggesting that it would at best be a part of a multidrug regimen.
We investigated the possible mechanisms by which ectopic Lxn
expression may suppress growth of lymphoma cells and found increased
apoptosis to be the major mechanism causing inhibition. Consistent with our
study of normal hematopoietic cells, our recent findings indicate that high Lxn
content is associated with more apoptotic cells, thus fewer stem cells

93

.

Apoptosis is controlled by the balance of both positive (pro-apoptotic) and
negative (anti-apoptotic) signals. We found that Lxn-induced apoptosis is mainly
through the down-regulation of anti-apoptotic genes, such as Bcl-2 and Pim-2.
Decreased level of Bcl-2 allows other pro-apoptotic proteins such as BAX and
BAK to aggregate, inducing cytochrome C release and caspase activation, and
apoptosis. Dysregulation of Bcl-2 is implicated in a variety of hematopoietic
malignancies.
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Three Pim-2 protein isoforms are active kinases which

phosphorylate pro-apoptotic protein BAD and dissociate its binding from Bcl-xL,
resulting in the inhibition of Bad-induced cell death.162, 163 Enhanced expression
of Pim-2 was detected in multiple B-cell lymphoma types164, T-cell lymphoblastic
leukemia/lymphoma165, and acute myeloid leukemia166. Thus our studies identify
Lxn as a novel regulator of the apoptotic pathway, in which it suppresses tumor
survival through the down-regulation of Bcl-2 and Pim-2 anti-apoptotic factors.
The well- known function of Lxn is the sole carboxypeptidase A inhibitor in
mammals.91 Therefore, it was plausible that other carboxypeptidase A inhibitors
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might mimic Lxn’s anti-tumor effects. A CPA inhibitor from potato tubers has been
shown to be an effective inhibitor of mammalian CPA and was therefore chosen
to test its anti-tumor properties. We found that it freely entered A20 lymphoma
cells but did not have suppressive growth effects via apoptosis, irrespective of
dose. Since CPAs are not expressed in A20 cells, we conclude that noncanonical functions of Lxn were responsible, yet unknown intracellular functions
of Lxn account for its anti-tumor effects. In addition, it is unlikely that tumor
suppressive effect of Lxn is through the regulation of ABGL2-mediated
microtubule tyrosination cycle, like TIG1, because we did not detect the
expression of ABGL2 in hematopoietic cells (data not shown). These results are
in line with findings of other investigations in which gene expression or protein
abundance regulated by Lxn were not related to carboxypeptidase inhibition
148

147,

. Thus, the action of mode of Lxn in regulating normal and malignant

hematopoiesis is not through its canonical CPA inhibitor activity. Future studies
aimed at identifying direct targets, or downstream signaling pathways, of Lxn will
be critical for our understanding of its function in normal and malignant
hematopoiesis.
Addressing the issue of why and how Lxn expression is down-regulated in
tumor cells, we found that CpG dinucleotides in regulatory regions of the Lxn
gene were methylated. Most human leukemia and lymphoma cell lines tested
showed strong patterns of methylation involving most of the 15 CpG
dinucleotides in Lxn promoter. This, in turn, led to a loss of gene expression that
was at least partially reversible. When cell lines were treated with de-methylating

131

reagent, 5-aza-2’-deoxycytidine, Lxn expression was re-initiated or up-regulated.
Thus, hypermethylation of the CpG island in the Lxn promoter may contribute to
silencing or down-regulation of Lxn expression in leukemia and lymphoma cells.
Ongoing studies will focus on the genetic and epigenetic regulation of Lxn
transcription in cancer stem cells, with promise for improved targeted approaches
for cancer prevention, diagnosis, and therapy.
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Figure 5.1. Decrease or loss of Lxn expression in leukemic and lymphoma
cell lines.
(A) Lxn mRNA expression in leukemia cell lines. Lxn mRNA level was measured
by quantitative real-time PCR and shown as mean (± 1 SD) (n=12). Control is
normal bone marrow (BM). (B) Lxn protein expression in leukemic cell lines
measured by western blot. The blot (bottom) and their quantification (top) profiles
demonstrate the absent or weak expression of LXN protein in leukemic and
lymphoma cell lines. Actin was used as the internal control.
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Figure 5.2. Hypermethylation of Lxn promoter CpG sites in leukemic cell
lines.
(A) CpG-enriched region in Lxn promoter. Sequence from 1500 base pairs
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upstream regulatory region to the first three exons was analyzed for CpGenriched sites (top). A CpG island with 252 base pairs (bps) length was identified.
The transcription starting site is indicated. Each filled circle represents a CpG
dinucleotide, and there are 15. (B) Bisulfite sequencing for Lxn promoter CpG
island methylation analysis in leukemic cell lines. Files are each of the 15 CpGs
and ranks are replicate clones sequenced for each CpG (n=3). Open circles
indicate unmethylated CpG (n=3) dinucleotides.

Filled circles indicate

methylated CpG dinucleotides. The methylation content was quantified by
dividing the number of methylated CpGs with total numbers of analyzed CpGs.
(C) Restoration or up-regulation of Lxn expression by 5-aza-2’-deoxycytidine. Lxn
mRNA was measured by quantitative real-time PCR in leukemic and lymphoma
cell lines exposed with or without 2uM 5-aza-2’-deoxycytidine for 4 days.
Expression levels were normalized to endogenous control, Gapdh. Results
shown are mean SD of 12 replicates from 3 independent experiments.
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Figure 5.3. Overexpression Lxn suppresses growth of A20 lymphoma cell
lines.
(A) In vitro growth inhibitory effects of Lxn overexpression on A20 cells. A20 cells
uninfected (A20 control) or infected with empty (vector control) or Lxn-containing
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vector (Lxn vector) were cultured for 20 days and counted by the trypan blue
exclusion method. The absolute cell numbers at indicated time-points (X axis)
were represented as log scale (Y axis) and were shown in left panel. The relative
tumor growth in Lxn-overexpression A20 cells to controls was shown in the right
panel. One representative experiment out of 3 independent ones is shown. (B)
Proportion of GFP+ A20 cells infected with empty (light grey column) and Lxncontaining vector (black column) throughout 20 days of culture. Flow cytometric
analysis was performed to detect GFP signal. (C) Western blot analysis with LXN
antibody in total protein lysate from A20 cells at day 20 culture showing durable
LXN overexpression. (D) In vivo tumor formation and growth with injection of
100,000 A20 cells. A20 cells were subcutaneously injected and tumor growth was
monitored and measured by all three dimensions of tumors (Y axis) on days
indicated on X axis. Shown is the compilation of 2 independent experiments with
 SD (n=12). The statistical significance is represented by * (p<0.005) and **
(p<0.05). (E) In vivo tumor formation and growth with injection of graded doses of
A20 cells. Graded doses of A20 cells (X axis) were subcutaneously injected and
tumor growth was monitored and measured in all three tumor dimensions (Y axis)
on days indicated on Z axis. Unfilled columns represent A20 cells infected with
empty vector and filled columns represent cells with Lxn-containing vector. A
representative experiment is shown (n=4/group). (F) The fraction of GFPexpressing A20 cells in tumors biopsied at 21 days. Single tumor cell
suspensions were made on day 21 post injection and subject to flow cytometric
analysis for GFP-expressing cells.
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Figure 5.4. Ectopic Lxn expression increases apoptosis of A20 cells.
(A) Flow cytometric analysis of cell cycle and apoptosis in cultured A20 cells. A20
cells without (A20 control) or with empty (vector control) or Lxn-containing vector
(Lxn vector) were cultured for 21 days. BrdU and 7AAD staining and flow
cytometric analysis was used for detecting different phases of the cell cycle
(G0/G1, S, G2/M) and apoptotic (A) and necrotic (N) population. A representative
flow cytometric file from Day 5 of culture is shown. (B) Down-regulation of antiapoptotic genes by Lxn overexpression. Apoptosis PCR arrays were performed
on A20 cells infected with empty or Lxn-expressing vectors. Left panel shows the
fold changes in the mRNA expression of several selected genes (as indicated in
X axis) in Lxn-overexpressing cells compared to the control. Western blot
confirms the decreased expression of Bcl-2 and two isoforms of Pim-2 at the
protein level in Lxn-overexpressing cells (arrowhead).

The other apoptosis-

related genes, such as Bcl-xl, Bax and Bad, did not show significant difference in
mRNA and protein expression. (C) The growth curve of A20 cells treated with
graded doses of potato carboxypeptidase inhibitor (PCPI). No significant
difference is detected between the control and any of the doses of PCPI. (D)
Internalization of PCPI to cytosol of A20 cells. A20 cells were cultured with
fluorescein isothiocyanate (FITC) labeled PCPI. Shown is a three-color
micrograph with PCPI in green (FITC), the B220 lymphoid cell surface marker in
red (phycoerythrin, PE), the nucleus in blue (DAPI), and merged image of red
and green as indicated.
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Figure 5.5. Decreased Lxn expression in stem/progenitor-enriched CD34+
cells in patients with leukemia and lymphoma.
(A) Lxn mRNA expression in bone marrow and peripheral blood CD34+ cells
from leukemia and lymphoma patients and normal individuals. Lxn mRNA level
was measured by quantitative real-time PCR and shown as mean (± 1 SD)
(n=12). Normal samples were derived from cord blood (CB), bone marrow (BM)
of young at 31 (Y1) and 39 (Y2) years old and old at 85 (O1) and 97 (O2) years
old people. The patient samples include acute myeloid leukemia (AML), T cell
pro-lympho leukemia (Pctl), plasma cell leukemia (PCL), acute T cell lymphoma
(ATLL) and acute lymphoid leukemia (ALL, preB phenotype). (B) LXN protein
expression in bone marrow and peripheral blood CD34+ cells from leukemia and
lymphoma patients and normal individuals. Western blot was performed on the
corresponding samples shown in panel (A) plus five more samples, including two
young (Y3 and Y4; at 40 and 31 years old respectively), two old (O3 and O4; at
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80 and 87 years old respectively) and chronic myeloid leukemia (CML). The blots
(bottom) and their quantification (top) profiles demonstrate the significantly
decreased Lxn protein level in leukemic CD34+ and lymphoma cells (P=0.03).
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Figure 5.6 Cpa3 is not expressed in A20 cells.
Real-time PCR was performed on A20 cells that were either uninfected (A20
control) or infected with empty (vector control) or Lxn expression vector (Lxn
vector) to quantify Cpa3 mRNA expression. The amplification plots for Lxn (A),
Cpa3 (B) and Gapdh (C) transcript show that Lxn is highly expressed in A20 cells
infected with Lxn expression vector whereas A20 and vector controls have very
low expression levels, consistent with the results in Fig. 5.3c. Cpa3 transcript is
not amplified in all types of cells, indicating it is not expressed in A20 cells. These
figures show the amplification plots of four individual biological replicates (n=4)
for each gene.
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Table 5.1 Carboxypeptidase A3 (Cpa3) is highly expressed in
stem/progenitor cells.
Probeset

1418625_s_at

1427995_at

1440617_at

Gene Title

carboxyglyceraldehyde- peptidase
carboxy3-phosphate
A3,
mast peptidase
dehydrogenase cell
A4

carboxypeptidase
A5

carboxypeptidase
A6

Gene Symbol

GAPDH

Cpa3

Cpa5

Cpa6

Chromosomal
Location

6 C 59.3cM

3 A2|3 13.2
cM
6 A3.3

6 A3.3

1 A2

Entrez Gene

14433

12873

71791

74649

329093

mean_y_B6

11982.87

391.33

20.43

16.17

11.43

proteolysis
/// and
peptidolysis

proteolysis
and
peptidolysis

proteolysis
and
peptidolysis

proteolysis
and
peptidolysis

GO Cellular
Component
cytoplasm
/// extracellular
Description
mitochondrion
space

extracellular
space

---

---

GO Biological glucose
Process
metabolism
Description
glycolysis

1448730_at

1453770_at

Cpa4

Expression level of CPAs were measured by microarray on a bone marrow
population null for cell markers characteristic of lineage-specific differentiated
blood cells (Lin-negative), and positive for the Sca-1 and c-Kit cell markers (LSK)
cells, enriched for hematopoietic stem/progenitor cells in mouse. The isolation of
LSK cells as well as microarray analysis was performed as previously described
158

except the array platform is mouse Genome 430 2.0 Array (Affymetrix). Three

biological samples were assayed, and the mean expression value (mean_y_B6)
for each gene in the table is the average of three readings. Cpa3 (highlighted in
gray) is the only Cpa gene that is highly enriched in LSK cells. Gapdh is the
endogenous control.
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CHAPTER 6: General Discussion and Conclusions
Adult stem cells in a variety of organs are responsible for replenishing
short-lived, mature cells as they become senescent. The proliferative and
regenerative capacities of adult stem cells make them ideal therapeutic tools for
treating the degenerative diseases and severe stresses such as tissue injury or
prevention of infection.
Our lab has uncovered novel features of adult hematopoietic stem cells,
by implementing a forward genetic approach. Using this approach, our lab has
identified several genes affecting stem cell population size and aging by
correlating phenotypic variation to genotypic variation. Recent studies in our lab
have demonstrated that endogenous stem cell numbers in young C57BL/6 (B6)
and DBA/2(D2) mice are regulated by several candidate genes including Lxn93,
Slit2 and p107 (manuscript in preparation). We learned that Lxn regulates
hematopoietic stem cell pool size through balancing apoptosis, proliferation and
self-renewal93. The studies outlined in this dissertation were designed to further
elucidate the functions of Lxn in regulating hematopoietic stem cell biology. To
serve this purpose, we generated a constitutive knockout mouse model in which
the Lxn gene was ablated in the entire organism. Several biological features
were analyzed in the Lxn null mouse model: First, I studied the phenotypes of
Lxn null cells in peripheral blood, spleen and bone marrow. A hyperproliferative
hematopoiesis was found in Lxn-/- mice. Experiments using an apoptotic marker
identified decreased apoptotic frequency in Lxn-/- BM cells. Thus, I hypothesize
that decreased apoptotic frequency was the primary mechanism underlying the
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expanded leukocytes and BM progenitor cell population in Lxn-/- mice (see in
chapter 2). Next, I explored the function of Lxn under genotoxic stress using
ionizing radiation as the stressor. Ionizing radiation breaks chemical bonds,
produce free radicals, and causes DNA damages167. DNA repair machinery is
triggered to amend the DNA damage; however, when the damage is too severe
to repair, apoptotic mechanisms are used to eliminate the damaged cells118.
Apoptosis is beneficial to retain chromosome integrity, but can also induce
cytopenia in hematopoiesis118. Pro-apoptotic genes such as p53 and Puma are
common pharmaceutical targets for treating radiation exposure because reduced
apoptotic activities accelerate hematological and immune recoveries168-173. In the
current studies, I found that Lxn-/- mice were more resistant to lethal and sublethal doses of radiation due to greatly accelerated hematological and immune
recoveries at one to six weeks after radiation50. The recovery advantage was
resulted from a reduction in apoptosis in stem and progenitor cell populations
(see in chapter 3). In another set of experiments, I studied the tumor suppressor
function of Lxn by overexpressing Lxn in B cell lymphoma cells. The
overexpression of Lxn up-regulated apoptotic frequencies in the lymphoma
cells107. High levels of Lxn inhibited tumor formation by these cells in vivo and
hindered tumor cell growth in vitro by inducing apoptosis (see in chapter 5)107.
From the studies described above, I hypothesize that Lxn negatively regulates
homeostatic cell expansion and radio-sensitivity of hematopoietic cells, and
suppresses hematological malignancies by mediating apoptosis. Lxn expression
levels are positively correlated with apoptotic activity (Fig. 6.1): High levels of Lxn
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increase apoptotic frequency in tumor cells and therefore inhibit tumor cell growth.
The down-regulation or absence of Lxn expression decreases apoptotic
frequency in the peripheral blood and BM leading to a proliferative hematopoiesis.
Loss of Lxn also confers radio-resistance by decreasing apoptotic frequency (Fig.
6.1). Thus, Lxn is an important mediator in response to hematological stresses,
and a potential recovery treatment for chemotherapy, radio-therapy and
hemorrhage.
As described above, apoptosis is one of the major mechanisms that
eliminates undesired and cancer-prone cells. However, a novel role of apoptosis
in controlling stem progenitor cell numbers and effecting stem cell-dependent
regeneration has been identified by Elaine Fuchs and Hermann Steller's group in
hair follicle stem cells. They found that mice deficient for a pro-apoptotic gene
Sept4/ARTS have elevated numbers of hair follicle stem cells and remarkable
improvement in wound healing and regeneration of hair follicles174. Our Lxn
deficient mice an advantage in hematopoietic regeneration after severe oxidative
stress (radiation) or after stem cell transplantation. There may be due to elevated
apoptosis in stem and progenitor cells by loss of Lxn as a pro-apoptotic regulator.
My studies did not definitively uncover the downstream signaling pathways
which underlie the altered apoptotic frequencies in Lxn-/- mice or in cancer cells
with Lxn overexpression. Two anti-apoptotic genes, Bcl-2 and Pim-2107, were
significantly down-regulated in murine lymphoma cells with Lxn overexpression.
Apoptosis is controlled by a balance between positive (pro-apoptotic) and
negative (anti-apoptotic) signals124. Decreased levels of Bcl-2 allow other pro-
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apoptotic proteins to aggregate, therefore, inducing apoptosis107.

The tumor

suppressor p53 is a negative regulator of Bcl-2 and the p53 signaling pathway is
central in ionizing radiation-induced apoptosis125,

126

. It is possible that the

mechanisms underlying Lxn induced-programmed cell death are involved in p53
and Bcl-2 mediated apoptotic signaling pathways.
Another potential candidate involved in Lxn induced-apoptosis is Thbs-1. I
found that the expression level of Thbs-1 was decreased in the Lxn-/- multipotent
progenitor cell population, in which the absolute number of cells increased
significantly (see in chapter 2). Thbs-1 null mice display a radio-resistance,
similar to what I observed in Lxn-/- mice130. Further, it has been reported that
Thbs-1 is involved in regulating radiation-induced apoptosis through a CD47mediated signaling pathway112,
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. To test this hypothesis, I will overexpress

Thbs-1 in Lxn-/- HSCs and transplant them into lethally irradiation recipients.
Three to four months post transplantation (when hematopoiesis is fully
reconstituted), the radio-resistance of the recipients will be examined. If, as I
hypothesize, overexpressing Thbs-1 in Lxn-/- cells will cause them to lose their
recovery advantage and become more sensitive to radiation exposure due to an
increased apoptotic frequency compared to empty vector transduced Lxn-/- cells.
In a final set of experiments, I demonstrated the effects of Lxn on HSC
migration activities and identified potential target gene(s) of Lxn that may
regulate HSPC mobilization (see in chapter 4). As described above, Thbs-1 is
down-regulated in the MPP population in Lxn-/- mice. Thbs-1 is an adhesive
glycoprotein that mediates cell-to-cell and cell-to-ECM adhesions. It binds to
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various adhesive molecules including fibrinogen, fibronectin, intergrin and
collagen10. It is possible that Thbs-1 mediates BM cell retention and mobilization,
and further regulates MPP cell numbers by influencing stem cell trafficking and
localization.
In conclusion, although yet far away from clinical application, my studies in
this dissertation have identified various novel functions of Lxn including inducing
proliferative hematopoiesis, responding to hematopoietic stresses, mediating
tumor formation, and regulating stem cell and progenitor mobilization. My studies
described the phenotypes of Lxn deficient animals; however, the mechanisms
and signaling pathways underlying these phenotypes have yet to be definitively
undetermined. In future experiments, I will study Lxn downstream signaling
pathways, focusing on the potential target genes of Lxn identified by microarray
analysis. I will examine the RNA expression profiles of candidate genes along the
developmental hierarchy, and determine the effects of Thbs-1 overexpression in
stem and progenitor cells using a retroviral vector. I hypothesize that performing
CAFC assays with Lxn-/- cells in which Thbs-1 is overexpressed will result in
decreased frequency of the primitive day 35 or later CAFC progenitor population.
Further, I speculate that overexpressing Thbs-1 in Lxn-/- cells will lead to
increased adhesion to stromal cells.
Ultimately, I would like to translate these findings in the mouse to the
treatments for human hematopoietic disorder. I hope these studies will aid in the
clinical practice of hematopoietic cell expansion in which expanded cells may be
used for accelerating hematologic and immunologic recoveries in patients
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exposed to high energy radiation, as well as in transplantation procedures for the
treatment of hematologic malignancies. My studies also discovered a novel role
for Lxn as a putative tumor suppressor gene. This role of Lxn could be used in
treatments designed to suppress the tumor cell growth and tumor formation in
hematologic diseases. The potential roles of Lxn in clinical and pharmaceutical
applications call for a detailed examination of the signaling pathways and
downstream regulators of the gene. For example, agonists of the Lxn signaling
pathway (which may stimulate downstream partners of Lxn) may promote
apoptosis in cancer cells; whereas antagonists (which block the Lxn signaling
pathway) may be utilized in expanding hematopoietic progenitor cells for
radiation victims, or facilitating hematopoietic reconstitution following stem cell
transplantation. The treatments of hematologic disorders using stem cell
therapies have advanced greatly in recent years. In this dissertation, I studied
various functions of Lxn in hopes of aiding the development of such therapies.
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Figure 6.1 Mechanisms of Lxn in influencing hematopoietic biology
through regulating apoptosis.
The expression of Lxn is positively correlated with apoptotic activities. Elevated
expression levels of Lxn increase apoptotic frequency in tumor cells and inhibit
tumor cell growth both in vitro and in vivo. Down-regulation of Lxn decreases
apoptotic frequencies in the peripheral blood and BM and results in a proliferative
hematopoiesis under homeostatic condition in Lxn-/- mice. Loss of Lxn
expression also confers a radio-resistance to Lxn-/- mice by decreasing
radiation-induced apoptosis.
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APPENDIX
Abbreviations

ALL
AML
ATLL
B6
BM
BrdU
CAFC
CB
CFU
CLP
CMP
CPA
CR
ECM
FBS
G-CSF
Gfm-1
GMP
HPC
HSC
HSPC
LK
LS
LSK
LT-HSC
Lxn
MEP
MPP
PBS
PCPI
PGE2
PI
PSGL-1
PTH
SCF
SDF-1
SP
ST-HSC
T-PLL
TBI
TIG-1

Acute lymphoid leukemia
Acute myeloid leukemia
Acute T cell lymphoma
C57BL/6 mouse
Bone marrow
5-bromo-2-deoxyuridine
Cobblestone-forming cell assay
Cord blood
Colony-forming cell unit
Common lymphoid progenitor
Common myeloid progenitor
Carboxypeptidase A
Competitive repopulation
Extracellular matrix
Fetal bovine serum
Granulocyte-colony stimulating factor
G-elongation factor, mitochondria-1
Granulocyte/monocyte progenitor
Hematopoietic progenitor cell
Hematopoietic stem cell
Hematopoietic stem and progenitor cell
Lineage-c-Kit+
Lineage-Sca-1+
Lineage-c-Kit+Sca-1+
Long term-hematopoietic stem cell
Latexin
Megakaryocyte/erythroid progenitor
Multipotent progenitor
Phosphate buffered saline
Potato carboxypeptidase inhibitor
Prostaglandin E2
Propidium iodide
P-selectin glycoprotein ligand-1
Parathyroid hormone
Stem cell factor
Stromal derived factor-1
Side population
Short term-hematopoietic stem cell
T cell pro-lymphocytic leukemia
Total body irradiation
Tazarotene-induced gene1
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